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decades, has led to incredible improvements in survival and quality of life of breast
cancerpatients. For example, in theUK in1971Ͳ72, the average age adjusted5Ͳyear
survival of any new diagnosed breast cancer patient (so all stages IͲIV combined,
including patientswith distantmetastases)was 52.2%,whereas in 2010Ͳ11 thiswas
86.6%.1 In The Netherlands, 5Ͳyear age adjusted survival has increased from 77% in
1989Ͳ1993 to 87% in 2008Ͳ2012.2 These results are spectacular andwould not have
been possible if thousands of researchers and millions of patients would not have




The spectacular improvement in survival is, besides great news for breast cancer
patients, ironically also badnews for breast cancer research. In away, breast cancer
researchisbecomingthevictimofitsownsuccessfortworeasons.First,studiesneedto
includemoreandmorepatientsbecausetheprognosisisfavorable:becauserecurrence




is thatwe need very long followͲup.Many breast cancer survivors live up to 10 to
20yearsorevenlongerandalthoughmanyrecurrencesoccurinthefirstfewyears,itis
known thatbreast cancer can recurmanyyearsafter initialdiagnosis.Thishas led to
studies needing at least 5 but more often 10 years of followͲup before clinicians,
insurance companies,governments,orother stakeholdersareprepared to implement
theresults. Ifawomanenrolls inabreastcancerstudytoday,and thenew treatment
proves tobe superior, itmay takeover10 to15 years for that treatment tobecome
standardofcare.
Requiring very large numbers of patients and very long followͲup are two major
problemsinbreastcancerresearchnowadays.Theycausestudiestobeveryexpensive,
as collecting, storing, and analyzing all the data from these patients is a very costly
process. Critics already state that the proportion of attention and funds that are
allocated to breast cancer research is too large, and other important diseases are




Another important issue in breast cancer research is whether the countless studies
actuallymeasure the sameoutcomes.Manydifferentendpointsareused, suchas for
survival: examples are overall survival, diseaseͲfree survival, eventͲfree survival, and
breastcancerspecificsurvival.Thesamegoes forrecurrence:examples includebreast
cancer recurrence, inͲbreast recurrence, local recurrence, ipsilateral breast tumor
recurrence, locoregional relapse, regional recurrence, and distantmetastasis. But do
they all measure the same thing? If they don’t, comparing them in reviews and
guidelines, or pooling them in metaͲanalyses would be like comparing apples and
oranges.Evenanendpointsuchas local recurrenceconsistsofasetofevents:breast
cancermayrecur in thesamebreast, in theotherbreast, in theskinorsubcutaneous
tissue,inthesurgicalscar,butsomemayalsocounttheotherbreastorlymphnodesas
local recurrences. This means that although “local recurrence” seems pretty





we use the available funds and efforts optimally.We can improve that by carefully
choosingbothǁŚŝĐŚoutcomewemeasureandforŚŽǁůŽŶŐweneedtomeasureit.The
aimofthisthesisistoavoidcomparingapplesandorangesinbreastcancerresearchto
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Results in breast cancer research are reported using study endpoints. Most are
composite endpoints (such as locoregional recurrence), consisting of several
components(forexamplelocalrecurrence)thatareinturncomposedofspecificevents
(suchasskin recurrence). Inconsistentendpointselectionanddefinitionmight lead to
unjustifiedconclusionswhencomparingstudyoutcomes.Thisstudyaimedtodetermine




PubMedwas searched for breast cancer studies published in nine leading journals in




TwentyͲthree different endpointswith a local or regional componentwere extracted
from 44 articles. Most frequently used were diseaseͲfree survival (25 articles),
recurrenceͲfree survival (7), local control (4), locoregional recurrenceͲfree survival (3)
and eventͲfree survival (3). Different endpoints were used for similar outcomes. Of
23endpoints, fivewere not defined and 18were defined only partially.Of these, 16
containedalocaland13aregionalcomponent.Includedeventswerenotspecifiedin33
of57(local)and27of50(regional)cases.Definitionsoflocalcomponentsinconsistently




Breast cancer studies usemany different endpointswith a locoregional component.
Definitionsofendpointsandeventsareeithernotprovidedorvarybetween trials.To







study endpoints and unclear definitions.Most studies have composite endpoints, for
example locoregional recurrence, that consist of several components. These
componentsconsistofspecificevents,suchasrecurrenceinaxillarylymphnodes.Both
the selection and definition of study endpoints (that is which specific events are
included)may vary between studies. For instance, survivalmay be reported using a
variety of endpoints, including diseaseͲfree survival, distant diseaseͲfree survival or








uniform breast cancer endpoint definitions.Definitions for neoadjuvant and adjuvant
trials were proposed by Hudis and colleagues3 in 2007 (Standardized Definitions for
EfficacyEndPointsinadjuvantbreastcancertrials,STEEP)andFumagallietal.4in2012.
Thesedefinitions,however,havenotbeenadopteduniversally into researchpractice.
Since its publication in 2007, the STEEP article has been cited by 125 individual
publications,accordingtoPubMedCentral,GoogleScholar,WebofKnowledgeandthe
Journal of Clinical Oncology website. A STEEP endpoint was used in 64 of these
publications.

Comparing or pooling the results of studies using different endpoints, or the same
endpointwithadifferentdefinition,mayresultinthecomparisonofapplesandoranges.
Therefore, comparing study results or pooling results in metaͲanalyses may not be
justified,andmayleadtoincorrectconclusions.Theaimofthisstudywastodetermine









The PubMed database was searched for experimental and observational research
investigatingbreast cancer inhumans.ThePubMed limits ‘clinical trials’, ‘randomized
controlled trials’ and ‘comparative studies’wereused, and the searchwas limited to
research published between 1 January 2011 and 31 December 2011 in nine leading










review if the abstract met the following inclusion criteria: original research paper;
observational or therapeutic study; investigation of any type of invasive early breast
cancer;anduseofaclinicalstudyendpoint.Articleswithstudyendpointscontaininga














compositeendpointwith a localor regional component). This resulted in inclusionof

























The 44 articles6–49 contained 23 different endpoints with a local and/or regional
component (Table 1.1). Various study endpointswere used for similar outcomes.Of
these 23 endpoints, diseaseͲfree survival was used most frequently (25 articles),
followedby recurrenceͲfreesurvival (7), localcontrol (4), locoregional recurrenceͲfree
survival (3) and eventͲfree survival (3). Twelve endpointswere used only once each
amongthe44publications.
Definitionsofendpointsused
Definitions of the endpoints were not provided consistently (Table 1.1). Five of
23endpointswerenotdefinedinanyofthepapers.Theother18weredefinedpartially


































events were included, or both. Of the 18 defined endpoints, 16 contained a local
componentand13aregionalcomponent.Twoendpointsweredefinedaccordingtothe





































(Table S1.1, supporting information). The definitions provided for these local
componentswerecomparedwithrespecttotheinclusionorexclusionofspecificevents.
Events listed in definitions of the local component of endpoints included ipsilateral






a local recurrence. In the remaining 24, at least some included events were listed
(Figure1.2). Tumour recurrence in breastwas included specifically15of 24 times. In
contrast, the breastwas notmentioned specifically six times. Three studies used an
alternativedefinitionforinͲbreastrecurrence:oneexcludedresectablerecurrencesafter
lumpectomy and the other two subdivided breast recurrences as true/marginal or
elsewhereinthebreast.Oneofthesepapersalsoincludedrecurrencesin‘nodalbasins’
asalocalevent.Noneoftheotherpapersmadeadistinctionbetweentruerecurrences








articles, excluded once (but included as a regional recurrence) and unclear in the
remaining19articles.
Definitionsofregionalcomponents




not specify the events that were considered regional recurrences. Fourteen of the
remaining23cases included recurrences in ‘lymphnodes’or ‘nodal’ recurrences,and
ninedescribedspecificnodalsitesthatwere included(Figure1.3).Thesesitesvaried in
the articles that provided this information; recurrences in axillary lymph nodeswere
specificallymentionedinnine,infraclavicularlymphnodesintwo,supraclavicularlymph
nodes in seven and internalmammary lymph nodes in seven. In six of the 23 cases,
lymph nodes were not mentioned in the definition. In the remaining three, the
endpointsdiseaseͲfreesurvival,breastcancerͲfreesurvivalandrecurrenceͲfreesurvival
were said to include ‘local or distant’ recurrences, but did not refer to inclusion or
exclusion of lymph node involvement. Of the 23 cases that listed the included and






















Figure1.2 Events included as local recurrence in endpoints for which at least a partial definition was



















Figure1.3 Events includedas regional recurrence inendpoints forwhichat leastapartialdefinitionwas
provided. Included ‘local and distant recurrence’,without furthermention of lymph nodes in









endpoint definitions were not provided consistently. For one in five endpoints, no
definition at all couldbededuced from the article; forothers,definitionswereoften
incompletewithrespecttothespecificevents includedorexcludedas localorregional




Inconsistencies intheselectionanddefinitionofendpointscan limit interpretationand
mutual comparison of trial results.Differences in study outcomes can be interpreted
incorrectlyasdifferencesintreatmenteffects,leadingtofalseconclusionsandpossible
delays in the implementationof important studyoutcomes in clinicalpractice.Breast
cancer studies are particularly vulnerable.Many new interventions show only small
improvements in outcomes, considering the already favourable prognosis of most






measure, all included components, and subsequently the events included in these
components,shouldmeetpredefinedcriteria.51First,theyshouldbeofsimilarrelevance
to patients. If patients consider distant metastases and death to be of similar
importance, it isnot importanthowariskreduction isdistributedbetweenthetwo. In
contrast, ipsilateral ductal carcinoma in situ (DCIS) is less important to patients than
mortality. In such instances, thedistributionof risk reduction is important,and isnot
reflectedproperly ifbotharecombined inoneendpoint suchasdiseaseͲfree survival.
Second,componentsshouldbeinfluencedtoasimilardegreebytheintervention.Ifan
intervention effectively prevents breast recurrence but not distant metastasis, one
endpointmeasuringbothdoesnotprovidespecificinformationontreatmenteffectand
may decrease the discriminative power of the study. The same applies tomortality,
particularlyinsubgroupsathighriskofnonͲbreastcancerdeath,whichisnotinfluenced
bythe interventiontothesamedegreeasbreastcancerͲspecificmortality.Inclusionof
allͲcause mortality in an endpoint can therefore distort the results.52–54 Finally, the
Chapter1
24
incidence of the more and less important components should be comparable. For





Clearly, not every endpoint currently used in breast cancer research meets these
criteria. The standard definitions proposed by Hudis et al.3 and Fumagalli and coͲ




oranticipatedproblems incomparingnewresultswithprevious findings.For instance,
theAmericanCollegeof SurgeonsOncologyGroup (ACOSOG) Z0011 study22 reported
diseaseͲfree survival rather than protocolͲspecified distant diseaseͲfree survival to
facilitate comparison with other studies. Additionally, these proposals focused on
traditional adjuvant therapy trials, whereas the multidisciplinary character of breast
cancer care requires easy comparison of results from other fields involved in
management of breast cancer. An additional consensusͲbased proposal for standard
definitionsofendpoints incancerresearch, includingbreastcancer,mightbeexpected
from the Definition for the Assessment of TimeͲtoͲevent Endpoints in CANcer trials
(DATECAN)group.55

The detrimental effect of inconsistent endpoint definitions on reliable comparison of
trial resultsmay be even largerwhen different events occur in the same patient. In
patientswith synchronousdistantmetastasisandaxillary recurrence, researchersmay
only count distant metastasis and ignore the axillary recurrence, or count distant
metastasisand include theaxillary recurrenceseparately inananalysisof locoregional













exhaustive,whichmay limitextrapolationoftheresults.Witha longertime frameand
additional journals, even more different endpoints and definitions could be
encountered. It is striking, therefore, that such a large variety of endpoints was
identifiedeveninthislimitedsearchandthatdefinitionswerenotprovidedconsistently.
Furthermore,manydifferentdefinitionswereusedforsimilarendpoints.Additionally,it
was found that the lack of definition of local and regional events lies at the root of
inconsistentendpointdefinitions.These inconsistenciessuggest thatdetailedendpoint
definitionsdonothavethefullattentionofauthorsandreviewers.Itisunlikelythatthis
problem is limited to theselectionof journalsor time frameof thesearch.Therefore,
despitetheserestrictions,theresultsillustratethattheoutcomesofmajorbreastcancer
studiesarenot readilycomparableasa resultof inconsistencies inendpoint selection
anddefinition.

To improve transparency, facilitate trial comparisonandavoidunjustified conclusions,
authors should provide clear and detailed definitions of the endpoints. Preferably,
standardendpointdefinitionsshouldbeused,tofacilitatereliablecomparisonofresults.
This also applies todefinitionsof the components included in theendpoints, such as
localand regionalevents.Toensure transparency inendpointdefinitions, clinical trial
registries, reviewers of research protocols and journals publishing the results should
insist on inclusion of detailed definitions of endpoints and their components. These
should comprise at least all included (and excluded) events and, for timeͲtoͲevent
endpoints, the starting point (for example from randomization, from surgery). The
ConsolidatedStandardsofReportingTrials(CONSORT)andSTrengtheningtheReporting




Designing standard endpoints for breast cancer trials should start with standard
definitions of the specific components of these endpoints, such as local or regional
recurrence.Onlywhenthedefinitionsofthesecomponentsareusedconsistentlycana
validandrelevantcombinationbechosenasavalidandrelevantcompositeendpoint.
Currently, a consensus project using the RAND/UCLA AppropriatenessMethod,56 an
adjustedversionoftheDelphimethod,aimingtoreachconsensusonthedefinitionsof
local event, second primary breast cancer, regional event and distant event, is being
undertaken.An international expert panelwas formed for this purpose, consisting of
leadingbreastcancerspecialists,epidemiologists,presidentsandmembersofscientific
and clinical societies and boards, research groups, and editors and editorial board






In anticipation of these proposals, authors reporting trial results should improve
transparencyintwoways.First,definitionsofallendpointsandtheircomponentsmust
be provided in the paper, so any differences in definitions between trials become
evident. Second, authors should report the incidence of all separate events in a
supplement, in addition to the incidence of the endpoint. For instance, a trial using
‘locoregionalrecurrence’astheprimaryendpointshouldalsoprovidethe incidenceof
all included events, such as ipsilateral recurrence in the breast, skin recurrence and
recurrence ina supraclavicular lymphnode.This improves transparencyeven further,
andmay help interpret conflicting results. As a result of these improvements,more
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The RANDͲUCLA Appropriateness method (modified Delphi method) was used. A






134 items in four categories. Localevent isdefinedasanyepithelialbreast canceror
ductalcarcinomainsitu(DCIS)intheipsilateralbreast,orskinandsubcutaneoustissue
on the ipsilateral thoracicwall. Second primary breast cancer is defined as epithelial
breastcancerinthecontralateralbreast.Regionaleventsarebreastcancerinipsilateral
lymph nodes. A distant event is breast cancer in any other location. Therefore, this
includesmetastasisincontralaterallymphnodesandbreastcancerinvolvingthesternal





inbreast cancer research. Futurebreast cancer researchprojects should adopt these







of these endpoints are not consistently provided and vary between trials.1 These
inconsistencies limittransparencyandcomparisonofstudyresults.For instance,when
interpretingdifferenttrials, it is importanttoknow if“breastcancer–free interval”and
“diseaseͲspecificsurvival”canbereadilycompared.Furthermore,evenifstudiesusethe
same endpoint terminology, these endpointsmay not include the same events. An
endpointsuchas“diseaseͲfreesurvival”mayincludelocal,regional,anddistantevents,
aswellasmortalityandsecondprimarycancer.Evenifanendpointconsistsofthesame
events (such as local recurrence), the specific components (eg, breast cancer in skin,









the incidence of the reported outcome. Therefore, there is need for standardized
definitionsofendͲpoints.Severalauthorshaveaddressedthisproblem.1Ͳ4Effortshave
been made to achieve uniform endpoint definitions in breast cancer research,
specifically for the neoadjuvant and adjuvant setting.5,6 Such proposals are important
steps towards overcoming this problem. Ideally, definitions are based on evidence
regarding incidence,prognosticandtherapeuticconsequences, importancetopatients,
anddegree towhich the component is influencedby the intervention.7However, for
many events in breast cancer research, solid evidence regarding these criteria is not
available.Therefore,expertconsensusisasuitablealternative.
The aim of this project was to achieve consensus on the definitions of the most
commonly used components in breast cancer study endpoints: local event, second










which was introduced in the 1950s for decisionmaking and forecasting formilitary
purposes.11 In aDelphi study, several rounds of questionnaires are completed by an
expertpanel.Theaim isconvergenceofopinionsastheprocessadvances,byallowing
panelmembers to adapt their opinions based on input from the panel. This is done
anonymously, tominimize the influence of seniority, presumptions of expertise, and
dominant characters. Since the introduction, the Delphimethod has been used and




The consensus process is summarized in Figure 2.1. First, a limited review of the
literaturewasperformedtoassesswhichitemsmaybeincludedaslocalevents,second
primarybreastcancers,regionalevents,anddistantevents.
Second, breast cancer experts were contacted personally by email to assess their
willingnesstoparticipate.Potentialpanelmemberswereselectedbasedonconsiderable






Third, the questionnaires were developed and distributed using SurveyMonkey
(SurveyMonkey, Inc., Palo Alto, CA; www.surveymonkey.com). The list of items was
basedontheliteraturereview,aswellassuggestionsfrombreastcancerexperts.Panel
memberswereaskedtoscoreonanineͲpointscalewhethertheyfound itappropriate





































werenot repeated. Items thatwereunclearorambiguousbasedoncomments in the
free text fieldswereadjustedand repeated. Itemssuggestedbypanelmemberswere
added.Forrepeateditems,themedianandrangeoftheratings,aswellasanyadditional
remarkswereprovided.Consequently,argumentsforratingthe itemwereavailableto

























A faceͲtoͲfacemeetingwasheldduring the SanAntonioBreastCancerSymposium in
December2013 to resolve any remaining issues. Panelmemberswho completed the
firstsurveywereinvited.Afterintroductionoftheitemwithpresentationofthemedian
rating,range,andanyadditionalremarks,the itemwasdiscussed.Afterthediscussion,
panelmembersratedthe itemagainonanineͲpointscale.This leadresultedeither in
agreement that the itemwas appropriate or inappropriate, or in the conclusion that



































The resultswere exported toMS Excel 2010 (Microsoft Corporation, RedmondWA).
Consensuswaspresentifthepanelratedtheeventappropriateorinappropriate(panel






Email invitations were sent to 40 persons (10 surgical oncologists, 10 medical
oncologists, eight radiation oncologists, five pathologists, three epidemiologists, and
fourotherprofessionals involved indesigning,publishing,or fundingofbreast cancer
research).Of40persons,26werewillingtoparticipateand11didnotrespond.Three






professional and research organizations, including American College of Surgeons
Oncology Group, American Society of Breast Surgeons, American Society of Clinical
Oncology, American Society for Radiation Oncology, Breast International Group,
Cochrane Breast Cancer ReviewGroup, ClinicalOncology Society Australia, European
Cancer Organisation, European Organisation for Research and Treatment of Cancer,
European Society for Medical Oncology, European Society for Radiotherapy and
Oncology, European Registration of Cancer Care, International Breast Cancer Study
Group,Medical Oncology Group of Australia, National Surgical Adjuvant Breast and
Bowel Project, Royal Australian and New Zealand College of Radiologists, Society of







The first questionnaire was sent to 26 people and completed by 24. The second
questionnairewassenttoallrespondentsofthefirstsurvey,andwascompletedby22
of24.All24panelmemberswereinvitedtotheconsensusmeeting,whichtookplaceat
the San Antonio Breast Cancer Symposium inDecember 2013. Eight panelmembers
attended.
FirstQuestionnaire
The first questionnaire consisted of 122 items in four categories,namely local event,
secondprimarybreastcancer,regionalevent,anddistantevent.Someitemswerelisted








and itemswhichwere replacedor clarified (n =27, replacing18 items from the first
























In the final meeting, items on which consensus did not exist after two rounds of
questionnaires were discussed. These items concerned a limited number of issues,
namely classification of breast cancer in skin and subcutaneous tissue (27 items in
categories local,regional,anddistantevent),distinctionbetween localeventsandnew
primary ipsilateral breast cancers (13 items in local event and secondprimary breast





true recurrence or second primary. Several potential factors, such as distance from
original tumor,histologic features,andmolecularsimilaritywere listedas items in the
categories“localevent”and“secondprimarybreastcancer”.Duringthequestionnaire
rounds, there was disagreement regarding the appropriate classification of events
occurringinanotherquadrantofthebreastthantheoriginaltumor,eventswithanother
morphology/histologic subtype, receptor switch (particularlynegative topositive),and
distinction based onmolecular characteristics such as loss of heterozygosity analysis.
Finally, for reasons of simplicity, heterogeneity within tumors, and lack of evidence
regarding prognostic significance of this distinction, the panel decided during the
meeting thatall ipsilateralepithelialbreast canceraswell asductal carcinoma in situ
(DCIS)shouldbeconsideredalocalevent.
The second topicofdebatewas isolated recurrence in contralateral lymphnodes (ie,
axillary,supraclavicular,infraclavicular,parasternal,orinternalmammary),inabsenceof
synchronousmalignancy ineitherbreastor synchronousdistantmetastasis. Initially,a
distinctionwasmade between contralateral lymph node events after sentinel lymph
nodebiopsy,axillary lymphnodedissection,oraxillaryradiotherapy,aswellasaftera
previously medially located tumor, and after inflammatory breast cancer. These
distinctionswere removed because of disagreement.Many panelmembers felt that
contralateral lymphnodeeventsareassociatedwithaworseprognosisthan ipsilateral
lymph node events, but a better prognosis than most distant events. Classifying
metastatic contralateral nodes as a separate category was considered. During the









Finally, thepaneldiscussedwhether tissue sampling shouldbemandatory for a first,
solitary lesionsuspected formetastasison imaging.Thepanel recommendedbiopsy if
feasible.Iftissuesampling isnotpossible(whichthepanelconsideredtobeveryrare),
unconfirmed first solitary metastasis is acceptable at the discretion of the treating
physicianor interdisciplinary tumorboard.Multiple lesionsconsistentwithmetastases





and subcutaneous tissue on the ipsilateral thoracicwall, are considered local events.
Secondprimarybreastcancerisepithelialbreastcancerinthecontralateralbreast(with
orwithoutnodalinvolvementonthatside).




parasternal, and internal mammary) in absence of synchronous ipsilateral or
contralateralbreastmalignancyordistantmetastasis,aswellasskinandsubcutaneous
tissue outside the ipsilateral thoracicwall. Pathology confirmation of a first, solitary




standardizeddefinitions of local event, second primary breast cancer, regional event,













































The definitions are designed for classification of events in research; they are not
intended toguide individualpatientmanagement.For instance,a recurrence invading
the chestwall aftermastectomy can be treatedwith curative intent for one patient,
consideringittobea“local”problem,whereasforthenextpatientitcanbeconsidered
equivalentto“distantdisease”asaconsequenceofage,comorbidity,and/orextentof
thedisease.Obviously,this isrelevant formanagingthe individualpatient. Incontrast,
registration of research data requires simplicity and consistency. Additionally,
techniques for classification must be available throughout the world. A molecular
techniquemay be promising to distinguish second primary breast cancer from true




This consensus isbasedon theopinionof24breast cancerexperts. Strengthsof this
approachincludeselectionofpanelmembersinalldisciplinesinvolvedinbreastcancer
careandmembersofmostmajorresearchgroupsandavarietyofprofessionalsocieties




opinions. Expert opinions do not constitute the highest level of evidence,which is a
second limitationof thisproject. Ifahigher levelofevidence canbeobtained, this is
desirable. In the case of events in endpoints, thiswould require consistent evidence
concerningprognosticandtherapeuticrelevanceofall items.Ideally,avalidcomposite
endpointconsistsofelementsthatareofsimilarprognosticsignificance, importanceto
patients,and incidence,andare influencedby the intervention toasimilardegree.7 If
thisisnotthecase,reportingtheincidenceofacompositeendpointmaybemisleading
anddifferences inprognosisor treatmenteffect instudyarmsmaynotbeadequately
reflected.Therefore, itwouldhavebeenappropriate toprovide information regarding
thesecriteriaforeach item.However, inthe lightofmajorchanges in localtreatment,
systemic treatment, and diagnostics in the last decades, specific informationwas not
available for most items. The lack of evidence concerning these criteria is both a
limitation of this study and the reason why formal expert consensus is a suitable
approach. Future research may illuminate prognostic and therapeutic relevance of
specific items, prompting adaption of thedefinitions. In themeantime, however, the
problem of inconsistent event definitions is so pressing that the use of standardized




Using uniform definitions of events in breast cancer research is essential for
transparencyandreliablecomparisonofresults.Earlier,Hudis6andFumagalli5proposed
standardized definitions of endpoints for the neoadjuvant and adjuvant setting. An
additionalproposalmaybeexpectedfromtheDefinitionfortheAssessmentofTimeͲtoͲ
event Endpoints in CANcer trials group.12 The current project strengthens these











treatment. Italso facilitatespresenting incidenceof specificevents in addition to the
primaryendpoint,aswassuggestedbyHudisetal.Adoptionofthesestandardizedevent
definitionswillimprovetransparencyandwillfacilitatecomparisonofstudyresults.This
effectwillbeparticularly pronouncedwhen authors report the incidence of separate
events (e.g., number of local events, regional events) in addition to the primary




and regulatory authorities. They should be integrated in coding rules for data
management.They shouldalsobeusedasbuildingblocks forcompositeendpoints in
publications. In addition, authors should report the incidence of separate events in
additiontotheincidenceoftheprimaryendpoint.
Inconclusion, theseconsensusͲbaseddefinitionsof localevent,secondprimarybreast
cancer, regionalevent,anddistanteventcanserveasbuildingblocks forendpoints in
breast cancer research. They should be adopted by datamanagers of breast cancer
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Panel members score each item on a nineͲpoint scale, where 1 equals “Very



















Disagreement was assessed according to the IPRAS Method as described in the
RAND/UCLA Appropriateness Method Manual8. Traditionally, the Appropriateness




70th percentile range is used because it most accurately reflects the traditional







as much on question 1 as they did on question 2. To correct for this problem,






TableB Example of the difference between interpercentile range (IPR) and interpercentile range
adjustedforsymmetry(IPRAS)inaninememberpanel
 Panelratings IPR30%Ͳ70% IPRASͲIPR
 Ă ď Đ Ě Ğ Ĩ Ő Ś ŝ 
Item1 ϭ ϭ ϯ ϱ ϱ ϱ ϳ ϵ ϵ 4 Ͳ1,65:disagreement


















































recurrence (CLNR). Traditionally, contralateral nodes are considered a distant site.
However, aberrant lymph drainage after previous surgery is common. This might




PubMedwas searchedupuntil July2014.ArticlesonCLNRwithorwithout ipsilateral
breast tumour recurrence (IBTR), and repeat sentinel node (SN) studies reporting on




24 articles were included, describing 48 patients. Of these 48, 26 patients had an
isolated CLNR, 7 IBTR and clinically detected CLNR and 15 IBTR with a positive























as the contralateral axilla, internal mammary chain or periclavicular sites.2Ͳ9
Hypothetically, these aberrant drainage patterns might indicate that a contralateral
lymph node recurrence (CLNR) after previous treatment for breast cancer should be
consideredasaregionalevent,ratherthansystemicdisease.
The prognostic impact and therapeutic consequences of CLNRs are not clear. If
prognosis of CLNR is comparable to the prognosis of an ipsilateral lymph node
recurrence itwouldsupport treatmentasaregionalevent,aiming forregionalcontrol
withcurativeratherthanpalliative intent.PrognosisofaCLNRmaydependontumour
andtreatmentrelatedfactors.First,prognosismaybeaffectedbysynchronousevents;
CLNR can occur isolated (i.e. without malignancy in either breast or other distant
events), or synchronous to an ipsilateral breast tumour recurrence (IBTR), or distant
event.Inmetastaticbreastcancer,prognosisisdeterminedmainlybythedistantevent.
In patients with a CLNR without distantmetastases, prognosis and the influence of
concurrent IBTRareunclear.Another relevantprognostic factormaybe thedetection






different prognostic impact compared to clinicallymanifestCLNRs. Initial locoregional
treatmentdefinesthechanceofdevelopingcontralaterallymphdrainagepatterns,asis














The selection process of the articles for this review is summarized in Figure 3.1. The
abstracts that were retrieved by the search were screened independently by two
authors(GVandMM)foreligibility,basedonpredefinedinclusionandexclusioncriteria.




sideas theCLNR),synchronousdistantevents,synchronousCLN involvementat initial
diagnosis(i.e.thecontralaterallymphnodewasnorecurrence),patientswhoseCLNwas
not breast cancer (i.e. benign, nonͲbreast malignancies), and if authors made no
distinctionbetweenCLNRandotherdistantevents.Patientswith isolatedtumourcells
(ITC) inacontralateralsentinelnodewereconsiderednodenegativeandthereforenot
taken into account for this analysis. Patients with micrometastases in contralateral
repeatsentinelnodeswereconsiderednodepositive,anddescribedseparately.Ofthe
selectedarticles,thefulltextaswellasthereferencelistwerereviewedindependently
by twoauthors (GVandMM). If the reference list containedpossibleeligiblearticles,
these were included. Disagreement was solved by discussion. From publications
reportingonmultiple individualpatients,only those individualsmeeting the inclusion
criteriawereselectedforthisreview.
DataͲextractionandstatisticalanalysis
Data extraction was performed independently by two authors (GV and MM).
Disagreementwas solved by discussion. The following characteristicswere extracted
from included publications: study design, whether it concerned CLNR with IBTR or
isolatedCLNR,initialTNMͲclassification,initialtreatment(axillary,breast,systemic),time
fromprimarybreastcancertoCLNR,detectionmethod,numberandlocationofaffected
CLNs, presence of synchronous metastatic ipsilateral lymph nodes, the method of
excluding occult breast cancer on the side of the CLNR, the method of excluding








node. Time to CLNRwithin these groups of patientswas compared using theMann
WhitneyhTest.PͲvalues<0.05wereconsideredstatisticallysignificant.Foroveralland
































Articles metinclusion criteria,fulltext review
n=44
Articles included infinal analysis
n=24
Exclusion based on exclusion criteria;n=386
ͲNot about breast cancer;n=31
ͲNot about CLN;n=308
ͲInvolved CLNnot breast cancer;n=6
ͲCLNisnot recurrence;n=21
ͲNodistinction CLNRandother distant events;n=1
ͲSynchronous contralateral breast cancer;n=6
ͲSynchronous distant event;n=3
ͲPublication type:comment n=2;animal study n=7;
conferencereportn=1
Exclusion during fulltext review;n=22
ͲFulltext not available;n=2Language;n=5
ͲGroupofpatients not exclusively breast cancer;n=2
ͲCLNidentified but not tumorͲpositive;n=7
ͲCLNnot recurrence or unclear if recurrence;n=3
ͲBreast cancer never confirmed;n=1
ͲNonew patients described;n=1
ͲNodetailson CLNR;n=1
Publications identified through Pubmed search
n=430




the reference lists, 2 additional eligible articles were obtained. In this stage,











Author Year N Articletype Detectionmethod 
    Clinical RepeatSNB
Jaffer 1995 1 Casereport X 
Daoud 1998 3 Retrospectivecaseseries X 
Lim 2004 1 Casereport  X
Schlechter 2004 1 Retrospectivecaseseries X 
Agarwal 2005 1 ProspectiverepeatSNBstudy  X
Roumen 2006 2 ProspectiverepeatSNBstudy  X
Taback 2006 2 ProspectiverepeatSNBstudy  X
Huston 2007 6 Retrospectivecaseseries X 
Wellner 2007 1 Casereport X 
Koizumi 2008 1 Retrospectivecaseseries  X
Kroon 2008 1 Casereport X 
Lanitis 2009 2 Retrospectivecaseseries X 
Tasevki 2009 1 Casereport  X
VanderPloeg 2009 2 Retrospectiveanalysisofprospectivecohort X 
Kinoshita 2010 1 Casereport X 
Kim 2011 2 Retrospectivecaseseries X 
Morcos 2011 6 Retrospectivecaseseries X 
Herold 2011 1 Casereport X 
Sabate 2011 1 Casereport X 
MaaskantͲBraat 2013 5 ProspectiverepeatSNBstudy  X
Kiluk 2014 3 Retrospectivecaseseries X 
Nishimura 2014 2 Casereport  X
Pasta 2014 1 Casereport X 
Tokmak 2014 1 ProspectiverepeatSNBstudy  X

















Total  26 7 15 48
TͲstage Tis 0 0 1 1(2.1%)
 T1 5 3 0 8(16.7%)
 T2 5 2 1 8(16.7%)
 T4 1 0 0 1(2.1%)
 Unknown 15 2 13 30(62.5%)
NͲstage N0 8 3 1 12(25.0%)
 N1mi 0 1 0 1(2.1%)
 N1 1 1 0 2(4.2%)
 N2 2 0 0 2(4.2%)
 N3 1 0 0 1(2.1%)
 Unknown 14 2 14 30(62.5%)
ERreceptorstatus Positive 6 2 0 8(16.7%)
 Negative 6 2 0 8(16.7%)
 Unknown 14 3 15 32(66.7%)
PRreceptorstatus Positive 4 2 0 6(12.5%)
 Negative 8 2 0 10(20.8%)
 Unknown 14 3 15 32(66.7%)
HER2receptorstatus Positive 5 0 0 5(10.4%)
 Negative 4 2 0 6(12.5%)
 Unknown 17 5 15 37(77.1%)
Breasttreatment BCT 10 5 11 26(54.2%)
 Mastectomy 4 0 1 5(10.4%)
 Unknown 12 2 3 17(35.4%)
Axillarytreatment ALND 11 7 11 29(60.42%)
 SNB 2 0 1 3(6.25%)
 None 0 0 1 1(2.1%)
 Unknown 13 0 2 15(31.25%)
Chemotherapy Yes 6 4 2 12(25.0%)
 No 4 1 2 7(14.6%)
 Unknown 16 2 11 29(60.4%)
Endocrinetherapy Yes 3 1 1 5(10.4%)
 No 6 3 1 10(20.8%)
 Unknown 17 3 13 33(68.75%)
Trastuzumab Yes 1 0 0 1(2.1%)
 No 6 4 2 12(25.0%)







Noneof the includedpatientspresentedwith inflammatorybreast cancer.TwentyͲsix
patients (54.2%) had undergone breast conserving therapy (BCT) and 5 (10.4%)
mastectomy,ofwhom2(4.2%)alsounderwentchestwall irradiation.The initialbreast
treatmentwasnotspecifiedinthepublicationfor17(35.4%)patients.Previoussurgery
of theaxillaconsistedofaxillary lymphnodedissection (ALND) in29 (60.4%)patients,
3(6.3%) patients underwent SNB only, 1 (2.1%) patient did not receive any axillary
treatment, and axillary treatment was not specified for 15 (31.3%) patients. For
19patients,theuseofadjuvantchemotherapyfortheprimarytumourwasregistered;
chemotherapywasadministered in12(63.2%)(Table3.2).Administrationofendocrine
therapywasdescribed for15of the48patients (31.25%),5ofwhom received some
formofendocrine therapy. Inpatientswithan isolatedCLNR, themean time interval
fromprimarytumourtoCLNRwas45.9months.Thiswas126.6monthsinpatientswith
CLNR and synchronous IBTR and 217.2 months in IBTR patients with a positive
contralateral sentinelnode.Time fromprimary tumour to thedetectionofCLNRwas
shorter in patients with an isolated CLNR; this difference was statistically significant
compared to patients with IBTR and clinically detected CLNR (p<0.001), as well as




firstgroup (N=26) concernedpatientswithan isolatedCLNR; the secondgroup (N=7)
consists of patients with an IBTR and synchronous CLNR detected clinically (i.e. at
physicalexaminationorduringthediagnosticworkͲup);thethirdgroup(N=15)consists
ofpatientswithanIBTRandapositivecontralateralsentinelnode(subclinicaldisease).
Physical examination was the most common method (45.5% of patients) to detect
clinicalCLNR(Table3.3).ThecontralateralaxillawasthemostcommonbasinforaCLNR,
with97.9%ofallCLNRs.OnepatientwithaCLNR in the internalmammarychainwas
described.9 In a total of 19 patients (39.6%) themethod of excluding a contralateral
breast tumour was recorded. This varied between prophylactic contralateral
mastectomy (N=2), to several radiological examinations; breast imaging was not
specified inonepatient, forotherpatientsmammographyonly (N=5),mammography






Almost all patients underwent surgery for their CLNR. ALND was performed in 34
(70.8%)ofallpatients,in3ofwhich(6.3%)itwascombinedwithregionalradiotherapy.
In the remaining patients, axillary radiotherapy only (N=2), resection of the affected
node(N=1)ornoaxillarytreatmentatall(N=1)wascarriedout. In10patients(20.8%)
regional treatmentwas not described (Table 3.3). Chemotherapy following CLNRwas
administeredin21patients(43.8%),endocrinetherapyin7patients(14.6%).In43.8%of
patients, administration of adjuvant systemic treatment was not described. Of the









N 26 7 15 48
Monthstorecurrence    
Mean 45.9 126.6 217.2 127.8
Median 34 108 138 69.5
Detectionmethod    
Clinically 12(46.2%) 3(42.9%) 0 15(31.3%)
US 2(7.7%) 0 0 2(4.2%)
PET  2(28.5%) 0 2(4.2%)
RepeatSNBa 1(3.8%) 0 15(100%) 16(33.3%)
Unknown 11(42.3%) 2(28.6%) 0 13(27.1%)
LNlocation    
Axilla 26(100%) 6(85.7%) 15(100%) 47(97.9%)
Internalmammary 0 1(14.3%) 0 1(2.1%)
LNtreatment    





















Unknown 5(19.2%) 1(14.3%) 4(26.7%) 10(20.8%)
Systemictreatment    
Chemotherapy 7(26.9%) 4(57.1%) 7(46.7%) 18(37.5%)
ChemoͲ&endocrinetherapy 3(11.5%) 0 0 3(6.3%)
Endocrinetherapy 0 0 4(26.7%) 4(8.3%)
None 2(7.7%) 0 1(6.7%) 3(6.3%)







To assess prognosis after CLNR, followͲup datawere analyzed. FollowͲup datawere
available for 23 patients (47.9%).Mean available followͲup time for all patientswas
50.3months.Overallsurvivalwas82.6%(95%CI67.1Ͳ98.1)anddiseaseͲfreesurvivalwas
65.2%(95%CI45.7Ͳ84.7). Inpatientswithan isolatedCLNR (N=13)themeanavailable
followͲuptimewas69.2months(range:7Ͳ408)whilethiswas23.5months(range:12Ͳ




CI19Ͳ73.2)werealivewithout locoregionalrecurrenceormetastasesat last followͲup.
Disease free survival of patients with IBTR and synchronous CLNR was 100% (N=4).









N 26 7 15 48
FollowͲupdataavailable 13(50%) 4(57.1%) 6(40%) 23(47.9%)
MeanfollowͲupafter
CLNR(months)
69.2 23.5 27 50.3
SurvivalatlastfollowͲup 10 4 5 19
Percentage 76.9% 100% 83.3% 82.6%
95%CI 54Ͳ99.8  53.5Ͳ100 67.1Ͳ98.1
Diseasefreeatlast
followͲup
6 4 5 15
Percentage 46.1% 100% 83.3% 65.2%






literature on the detection, treatment and prognostic impact of CLNRs. Literature is
scarceandconsistsofmostlysmallstudiesandcasereͲports,inwhichthelevelofdetail






prognosis of metastatic breast cancer. Furthermore, the majority of the patients
received surgical (92.1% of patients) and systemic treatment (88.9%), suggesting a
curative instead of palliative intent. Therefore, the classification of CLNR as distant
diseasedoesnotseemjustified.
The origin of CLNR may be different to the origin of metastatic disease. Distant
metastases occur due to systemic circulating spread of tumour cells. CLNR might
originate due to aberrant lymph drainage from the ipsilateral breast to contralateral
nodalbasins,similartoipsilaterallymphnoderecurrences.Lymphaticdrainagefromthe
breast towards the ipsilateralaxilla iswellestablishedandwasdescribed for the first
timebytheFrenchanatomistSappey, in1874.32Lymphdrainageoutsidethe ipsilateral
axilla occurs in 20Ͳ57% of primary breast cancer patients.3,5,33 This depends on the
sentinelnode identification technique (e.g. injection site,amountand typeof tracer),
and consists mainly of drainage to the internal mammary chain. Drainage to the
contralateralaxillaismorerare,occurringin0Ͳ2%atinitialdiagnosis.34,35However,after
previoussurgeryorradiotherapyofthebreastoraxilla,aberrantdrainagepatternsare
morecommon.Overall,drainageoutsideofthe ipsilateralaxilla isdescribed in18Ͳ70%
afterprevioussurgeryorradiotherapyforbreastcancer.4Ͳ6Drainagetothecontralateral
axilla has been described in 14.7% of patients, in the largest available repeat SNB
study.12 Aberrant drainage occurs more frequently after previous ALND, than after
previousSNB.12Therefore,CLNRcouldbecausedbyaberrantlymphdrainage,especially
afterprevioussurgeryoftheipsilateralbreastoraxilla.
It isremarkableand in linewithrepeatSNBstudiesthat inthisstudy,18of20patients
(90%)with an IBTR and synchronousCLNR, forwhom informationonprimary axillary
treatmentwasavailable,hadundergoneALND.ThissupportsthehypothesisthatCLNR
are regionalnodalmetastasesof the IBTR,arising fromaberrant lymphdrainageafter
ALND. Isolated CLNR should be regarded as a different entity than an IBTR with
synchronous CLNR. In this review, a difference in time to recurrence was observed
betweenthesetwoentities; isolatedCLNRsoccursignificantlyearlier(34months)than
IBTRs with synchronous CLNR (108 and 138months for clinically detected and SNB
detected CLNR, respectively). This suggests that isolated CLNR could be an occult
contralateralnodalmetastasisoftheprimarybreastcancer,remaininginsituduringthe
treatment of the primary breast tumour. Since the involvement of CLNs is seldom
assessed inbreastcancerpatients,small tumourburden inaCLNwouldgounnoticed
anduntreated.Eventually,this initiallysubclinicaldiseasecoulddevelop intoaclinically
detectableCLNR.








metastases to only 13% in patients with visceral metastases.38 We observed some
variation in overall and diseaseͲfree survival amongst different subgroups of CLNR
patients,butthesmallnumbersdonotallowformalstatisticaltesting.
AnotherobservationfromthisreviewconcernstreatmentofCLNR.AlthoughaCLNR is
traditionally considered distantmetastatic disease,most patients received surgical as
well as systemic treatment.A total of 89.5% of patients underwent surgery for their
CLNR. In patients with available data on systemic treatment, chemotherapy and/or
endocrine therapywasadministered in77.8%.The frequentuseof surgery combined
withsystemictreatment impliesthatcliniciansaretreatingthesepatientswithcurative
rather than palliative intent, and appear to regard CLNR as a regional rather than a
distant event. In addition to treatment decisions, prognosis of CLNR should have
consequencesforeventregistrationinbreastcancerresearch.Forregistrationpurposes,
a composite endpoint should consist of events with similar prognostic impact,39
otherwise the clinicalmeaning of the endpoint is unclear. If prognosis after a CLNR
differs from theprognosisofdistantevents,CLNRs shouldno longerbe registeredas
distantmetastasesinbreastcancerresearch.40
Due to the retrospective character of this study and the small number of included
patients, some limitationsneed tobe consideredwhen interpreting the results. First,
reportingbiasmayhaveoccurred.Ourreviewconsistsmostlyofcasereportsandsmall
retrospective studies.Since itmightbemore likelytoreportonremarkablecasesand
prognostic extremes, this may have led to both overestimation as well as
underestimationofprognosis.Additionally,thesmallnumberofpatients,particularlyin
thesubgroups,isanimportantlimitationofthisstudyandlimitedcomparisonsofoverall
and diseaseͲfree survival. Also, themean followͲup time of patientswith an isolated
CLNR was much longer than followͲup time of patients with IBTR and CLNR. It is
important toput survivaldifferences into theperspectiveof available followͲup time,
sincemoreeventsmightoccurduringthecourseofalongerfollowͲup.
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phenomenon is unknown, we would suggest that CLNR should be included in a
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((((contralateral[AllFields]OR (contralateral[All  Fields]AND (“axilla”[MeSHTerms]OR
“axilla”[All Fields]))) OR (contralateral[All Fields] AND (“axilla”[MeSH Terms] OR
“axilla”[All Fields])))AND (((((“lymphnodes”[MeSHTerms]OR ((“lymph”[MeSHTerms]
OR “lymph”[All Fields]) AND nodes[All Fields])) OR (“lymph nodes”[MeSH Terms] OR
(“lymph”[All Fields] AND “noͲ des”[All Fields]) OR “lymph nodes”[All Fields])) OR
((“lymph”[MeSH Terms] OR “lymph”[All Fields]) AND node[All Fields])) OR (“lymph
nodes”[MeSHTerms]OR(“lymph”[AllFields]AND“nodes”[AllFields])OR“lymph
nodes”[AllFields]OR (“lymph”[AllFields]AND “node”[AllFields])OR “lymphnode”[All
Fields]))OR “LymphNodes”[Mesh]))AND (((((((“breastneoplasms”[ͲMeSHTerms]OR
“breast neoplasms”[MeSH Terms]) OR (“breast neoplasms”[MeSH Terms] OR
(“breast”[All Fields]AND “neoplasms”[All Fields])OR “breastneoͲplasms”[All Fields]))
OR((“breast”[MeSHTerms]OR“breast”[AllFields])AND(“neoplasms”[MeSHTerms]OR
“neoplasms”[All Fields]))) OR ((“breast”[MeSH Terms] OR “breast”[All Fields]) AND
(“neoplasms”[MeSH Terms]OR “neoplasms”[All Fields]OR “cancer”[Ͳ All Fields])))OR
(“breastneoplasms”[MeSHTerms]OR(“breast”[AllFields]AND“neoplasms”[AllFields])
OR “breastneoplasms”[AllFields]OR (“breast”[AllFields]AND “cancer”[AllFields])OR
“breast cancer”[All Fields])) OR ((“breast”[MeSH Terms] OR “breast”[All Fields]) AND
(“carcinoma”[MeSH Terms] OR “carcinoͲ ma”[All Fields]))) OR (“breast



































contralateral lymphnode (CLNR).At initialdiagnosis,thesearetraditionallyconsidered
distantevents.However,after treatmentofbreastcancer,aberrant lymphdrainage is





Cases of CLNRwere identified in two national cancer databases and three individual
hospital databases. Endpoints were overall survival (OS) and breast cancer specific




A total of 183 cases of CLNR were identified. Median age at initial diagnosis was
56years.Yearofinitialdiagnosiswas2005orlaterin51patients(27.9%),1995Ͳ2004in
46 (25.1%), and before 1995 in 85 (47.0%).Median time to CLNR was 25months.
MedianfollowͲupafterCLNRwas26months.FiveyearOSwas30.2%,thiswasslightly






OS after CLNR was poor at 30.2% after 5 years, BCSS was similar to OS. Patients
diagnosedmorerecentlyhadslightlybetterprognosis.Althoughthisstudy isatriskfor
underestimation of prognosis, it suggests that prognosis is worse than after ILND






After treatment for breast cancer, some patients experience recurrence in a
contralateral lymph node (CLNR). When positive contralateral lymph nodes are
encountered at initialdiagnosis, theyare traditionally considereddistantmetastases.1
However, after breast cancer treatment, aberrant lymph drainage is common,
particularlyafterradiotherapyandaxillarysurgery.2Ͳ10Thismaymeanthatcontralateral
lymph nodes are actually the first basins that lymph from the treated breast drains




breast tumor recurrence (IBTR), for instance by PET(ͲCT) or repeat sentinel node
procedure.Astheseareincreasinglyused,wemightdetectmoreCLNRthanpreviously.
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larger population to determinewhether it should be seen as a regional or a distant
recurrence.
Methods
Retrospectivedataon theoccurrenceandprognosisofCLNRwerecollected from two
national databases as well as from individual hospital databases (Table 4.1). Local
collaborating physicians who obtained the data from patient’s records supplied
informationfromindividualhospitals.Datawereprovidedwithoutpatientidentifiersina
secure file format. The local institutional review boardwaived the need formedical
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ethicalapprovaland informedconsentofpatients,as informationcouldnotbe traced
backtoindividualpersons.
Selectionofpatients
Inclusion criteria were patients 18 years of age or over, with a previous history of
curative treatment for invasivebreastcancer,withpathologyconfirmedbreastcancer
recurrence inacontralateral lymphnode (i.e.contralateralaxillary, internalmammary,
supraͲorinfraclavicularorintramammarylymphnode).TheCLNRcanbeeitherisolated
(i.e.inabsenceofipsilateralbreastrecurrence),orsynchronouswithanIBTR.
Exclusion criteria were objection of the patient to use data for research purposes,




Patientswere identified by searching national databases. The first databasewas the
Netherlands Cancer Registry (Comprehensive Cancer Organisation the Netherlands,
IKNL).Traineddata registrationclerksobtained thedata frompatients’charts fromall






Individualcaseswereobtained fromhospitaldatabases from threehospitals:Klinikum
Esslingen (Esslingen, Germany), Helsinki University Hospital (Helsinki, Finland), and














diagnosis. BCSS status (i.e. cause of death)was not registered for the Dutch cancer
registry population.As thesemissing values are not random and theDutch database
formed a significant proportion of the total study population, including them (and
treatingthemeitherasbreastcancerdeathsornonͲbreastcancerdeaths)woulddistort
















Source N= Yearofinitialdiagnosis Outcomesavailable
Dutchnationalcancerregistry(IKNL) 25* 2005Ͳ2008 OS
Danishnationalcancerregistry 152 1978Ͳ2012 OS,BCSS
HelsinkiUniversityHospital,Finland 2 2000Ͳ2002 OS,BCSS,DM
KlinikumEsslingen,Germany 2 2012 OS,BCSS,DM





A totalof183casesofCLNRafterbreastcancer treatmentwereavailable from these




(47.0%)werediagnosedbefore1995.Patient and tumor characteristics are shown in
Table4.2.Medianageatinitialbreastcancerdiagnosiswas56years.Mosttumorswere
pT1 and pT2 and only 41 (22.4%)were pN0 at initial diagnosis. Receptor statuswas
unknownforaconsiderablenumberofpatients.ERwasknownfor111patients(60.7%),
ofwhich 75were ER+ (67.5%, 41% of total).Her2 statuswas known for 61 (33.3%)
patients,ofwhich17wereHer2+(27.9%,9.3%oftotal).Mastectomywasperformedin
153(83.6%)ofpatients.Thispercentagewasslightlyhigherinpatientsdiagnosedearlier;
i.e. 94.2% when diagnosed before 1995, 73.9% when diagnosed between 1995 and
2004,and74.5%whendiagnosedfrom2005.
Themedian time from diagnosis to CLNR was 25months (mean 38months, range
0.7Ͳ264).LocationanddetectionmethodoftheCLNRwasunfortunatelyunknowninthe
majority of cases (170/183, 92.9%), aswas the number of affected nodes (175/183,
95.6%).
TreatmentafterCLNRwasalsounknown fora largenumberof subjects. In the cases
withcompletedataontreatment,surgeryoftheaffected lymphnodeswasperformed
in 19/34 (55.9%) of subjects, radiation therapy was performed in 16/36 (44.4%),
chemotherapy was administered to 18/35 (51.4%) and endocrine therapy to 16/36
(44.4%).
Survivalanalysis
Themedian followͲup after diagnosis of CLNR for OS was 26.3months (mean 44.0
months,range2.4Ͳ346.3).MedianfollowͲupwas39.9months(mean38.8)intheDutch
database, 26.2months (mean 45.3) in theDanish database, and 25.3months (mean
31.0)inthecasesfromtheindividualhospitals.OSdatawascompleteforall183cases.




(seeMethods section). Subsequently, BCSS data were available for 158 subjects, in
whichmedianfollowͲupwas26.2months(mean44.8,range2.4Ͳ346.3).Byexclusionof
the Dutch Cancer registry patients, the subjects included in the BCSS analysis were
diagnosed earlier, namely before 1995 in 86 of patients (54.4%), between 1995 and
2004 in 46 (29.1%), and in 2005 or later in 26 (16.5%). Of the included patients,
29(18.4%)werealiveatlastfollowup,110(69.6%)diedofbreastcancer,6(3.8%)died
ofanothercancer,7 (4.4%)diedofanothercause,and6 (3.8%)diedofanunknown







Ageatinitial Median(range) 56(26Ͳ87) Yes 79(43.2%)
diagnosis   No 46(25.1%)




pT3 27(14.8%) Yes 67(36.6%)







pN0 41(22.4%) Yes 8(4.4%)























Her2unknown 122(66.7%) Yes 9(15.8%)





Medullary 4(2.2%) Yes 19(10.4%)





Mastectomy 153(83.6%) Yes 16(8.7%)Initialbreast





SNonly 5(2.7%) Yes 18(9.8%)






Yes 64(35%) Yes 16(8.7%)







ER estrogen receptor, PR progesterone receptor,BCS breast conserving surgery,ALND axillary lymph node
dissection, SN sentinelnodeprocedure, IBTR ipsilateralbreast tumor recurrence,CLNR contralateral lymph
noderecurrence.*mostextensivesurgerylisted,iffirstSNBandthencompletionALND,orfirstBCSandthen
mastectomy,onlyALNDandmastectomyare counted respectively.#nodal samplingwasperformed in the
Danishstudypopulation
Prognosisdependingonyearofdiagnosis
ParticularlytheDanishdatabase includeda largenumberofpatientswhowere initially
diagnosed several decades ago. OS in categories depending on year of initial breast
cancer diagnosis is shown in Figure 4.2. OS after 24 and 60 months for patients
diagnosed in2005or laterwere72.4%and33.6%respectively.Forpatientsdiagnosed
between1995and2004,24monthOSwas73.4%and60monthOS46.1%.Inpatients
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Months 0 12 24 60 120
No.atrisk     
>2005 51 43 27 8 0
1995Ͳ2004 46 41 33 19 6








2005 and 2008), 75 (/34453, 0.2%) cases of ILNR without simultaneous distant
metastaseswere identified.Median time to ILNRwas 23.1months (range 2.8Ͳ59.4).
Median followͲup after ILNRwas 45.9months (7.9Ͳ93.5).Overall survivalwas 73.3%
after2years57.4%after5years(Figure4.3a).
From the same database, 2948 (/34453, 8.5%) cases of distantmetastases as a first
event were identified. Median time to distant metastasis was 26.2 months (range
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Months 0 12 24 60 96
No.atrisk 2948 1819 1113 197 13
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This study, investigating prognosis after breast cancer recurrence in a contralateral
lymph node (without simultaneous distant metastases), in 183 patients from two
nationalcancerregistriesandthree individualhospitaldatabases,showsthat5yearOS





although BCSS datawas availablemainly for patientswhowere diagnosed in earlier
decades.AlthoughinformationonlocalandsystemictreatmentofCLNRandpresenceof
simultaneous ipsilateralbreast tumorrecurrencewasmissingandresultscouldnotbe




Themajorstrengthof thisstudy is that it is the largestcompilationof informationon
prognosisofCLNRwithoutsimultaneous(other)distantmetastasestodate.Limitations




were diagnosed as early as in the 1970s, which means both initial treatment and
treatment of the CLNR itself (particularly systemic) may be suboptimal to current
standardswhichmay leadtounderestimationofprognosis inthisstudy.Italsomade it







of favorable results.Asecondexplanationmaybe that47%ofpatients in thepresent
study were diagnosed before 1995. Although this may usually bias towards
underestimation of prognosis, the separate analysis of patients diagnosed after 2005
showed slightly better prognosis compared to earlier cohorts, but still inferior to





more favorableprognosis than isolatedCLNR.Due tomissingdata (only9 caseswith
knownIBTR+CLNR,unknownfor145subjects),thiscouldnotbeexploredfurtherinthe
current study and an overrepresentation of isolated CLNRmay have lead to inferior
prognosis.Finally,dataontreatmentafterCLNR(localandsystemic)weremissingforan
important part of the study population. As a result, we could not explore whether
patientsweretreatedwithcurativeintentandhowthisaffectedprognosis.

In summary, this study shows that CLNR has a 5Ͳyear OS of 30%, which is inferior
compared to ILNR but better than distant disease in the current era. In literature,
ipsilateral locoregionalrecurrence(breastand/or lymphnodes)hasa5ͲyearDFSof56Ͳ
84%.13Ͳ15TherandomizedCALORtrialincludedpatientswithcompletelyexcisedisolated
locoregional recurrence,and showed5ͲyearDFSof69% (56Ͳ79%)with chemotherapy
and57% (44Ͳ67%)without chemotherapy.16 Theseoutcomesare similar to5ͲyearOS
after ILNR (with/without ipsilateral breast tumor recurrence) thatwas calculated for







although better than prognosis after DM, notwithstanding a potential risk for
underestimation of prognosis in this study. Future evidence on recent cohortsmay
illuminate this issue further, includingthedifferencebetween isolatedCLNRandCLNR
with synchronous IBTR.For instance, repeat sentinelnode studiescouldprospectively
evaluate prognosis of the patients in which CLNR were present. Up until then, we
suggestthatCLNRisclassifiedasadistanteventinbreastcancerresearch.However,in
clinicalpractice,itisconceivablethatphysiciansdeterminetotreatwithcurativeintent
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status inbreast cancerpatients consistsofpresenceofan infraclavicular lymphnode







status as pathologic result. Patientswith pN3awere subdivided in pN3a based on at
leastan infraclavicular LNMor ш10axillary LNMs.DiseaseͲfree survival (DFS) included
any local, regional or contralateral recurrence, distant metastasis or death within
5years. KaplanͲMeier curves provided information on 5Ͳyear DFS and 8Ͳyear overall




A total of 3400 patientswith pN2a and 1788 patientswith pN3awere included. In
83patients, pN3a was based on at least an infraclavicular LNM (4.6%) and in
1705patientsbecauseof ш10 axillary LNMs (95.4%).Aftermultivariable analyses,DFS






PN3a status based on an at least an infraclavicular LNM is rare, yet its prognosis is






In 1958, the first edition of the tumourͲnodeͲmetastasis (TNM) classification of
malignant tumoursof thebreastwaspublishedby theUnion for InternationalCancer
Control (UICC) in order to achieve worldwide consensus for the classification of,
eventually,eachsolidtumourtype.1Subsequently,thisclassificationsystemwasrevised
eachdecadeto implementnew insights.For instance,the introductionofneoadjuvant




pN1 (movable axillary LNMs) and pN2 (fixed axillary LNMs).3 After revision in sixth
edition, the number of axillary LNMs was incorporated as key element in the
classification,asimpairedprognosiswasdemonstratedinthepresenceofanincreasing
numberofaxillaryLNMs.4Thisresulted infourcategories:pN0(0axillaryLNMs),pN1a
(1Ͳ3 axillary LNMs), pN2a (4Ͳ9 axillary LNMs) and pN3a (ш10 axillary LNMs).5
Furthermore,astudybyNewmanetal.observedaworsediseaseͲfree(DFS)andoverall
survival (OS) in patientswith infraclavicular (level III) and axillary LNMs compared to
patients with axillary LNMs only (DFS 50% versus 68%; OS 58% versus 83%,
respectively).6Asa consequence, theUICCdecided to redefine infraclavicular LNMas
pN3a in the sixth edition; in contrast to earlier, when an infraclavicular LNM was
consideredequivalent tootheraxillaryLNMs in the fifthedition.CurrentlypN3anodal
status consists of patientswith ш10 axillary LNMs and of patientswith infraclavicular
LNM.7
ThecombinationofbothgroupswithinpN3asuggeststhattheirprognosis issimilar.8,9






Data were obtained from the Netherlands Cancer Registry (NCR), managed by the
Netherlands Comprehensive CancerOrganisation (IKNL). The NCR collects data of all
patientsdiagnosedwithanytypeofcancerintheNetherlands,afteranotificationofthe
PALGA (‘Nationwide network and registry of histoͲ and cytopathology in the
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Netherlands’) system. Afterwards, trained data collection registrars from the NCR
extracteddatafrompatients’recordsconcerningpatientcharacteristics,treatmentand
followͲup.
In this study, all patients diagnosed between 2005 and 2008 with primary invasive
epithelialbreastcancerandpN2aorpN3astatusesas the finalpathologic resultwere
included.Exclusioncriteriaweresynchronousbreastcancer,distantmetastasesattime
of diagnosis (or within 91 days) or an unknown number of LNMs. Patients without
surgerywerealsoexcluded.Datawerecollectedonage,tumourtype,receptorstatus,










According to the national guideline of 2005, regional treatment depended on nodal
status: sentinel lymph node biopsy (SLNB) in case of clinically node negative status,
basedonphysicalexamination (axillaryultrasoundwascommonbutnotmandatoryat





wasadvised inallpremenopausalwomenand inwomen<69 yearsoldwithestrogen
(ER)andprogesterone(PR)tumours.Inpostmenopausalwomen,aged50Ͳ59yearswith















metastasis ormortality within 5 years after the primary diagnosis. Events occurring
0Ͳ91daysafterdiagnosiswereconsideredsynchronoustotheoriginaltumourandnot
counted as recurrences.Date of death or date of emigrationwere derived from the
MunicipalPersonalRecordsDatabaseandcompleteduntil31stDecember2014.Patients





clinicopathological variables associated with DFS and OS were examined using
univariable and,where applicable,multivariable Cox proportional hazards regression,
with hazard ratio (HR) and corresponding 95% confidence intervals. The number of




topatientswithpN2a (i.e.4Ͳ9 axillary LNMs),by calculatingKaplanͲMeier curvesand
comparing with the logͲrank test. In addition, univariable and multivariable Cox




between2005and2008 in theNetherlands,ofwhom3442patientshadpN2a (6.6%)
and 1799 patients (3.5%) had pN3a status (Figure 5.1). Eventually, 83patientswere




36mm,p=0.032)and,obviously,had fewerpositive lymphnodes (mean6 versus15,
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Five year followͲupwas available for 1293 patients (72.3%, n=58 versus n=1235, for
patientswithat leastan infraclavicularversus ш10axillaryLNMs).Within5yearsafter
diagnosis,43.6%experiencedafirstlocoregionalorcontralateralrecurrenceordistance
metastasis and 6.9% deceased. Thus 50.5% of the patients experienced an event,
resultinginaDFSof49.5%.Insubgroupanalyses,DFSwas63.8%inpatientswithatleast
an infraclavicular LNM and 48.8% of patients with ш10 axillary LNMs (p=0.018)
(Figure5.2a).
InmultivariableCoxregressionanalyses,theeffectofhavingш10axillaryLNMsonDFS
was significant (HR 1.59, W=0.036) (Table 5.2). Receiving chemotherapy (HR 0.51,
p<0.001) and radiation therapy (HR 0.59, p<0.001) were identified as significant






















LNM 58 57 49 45 37 23
ш10axillary


























LNM 83 81 73 68 63 61 56 26 12
ш10axillary
LNMs 1705 1607 1444 1288 1130 1004 912 627 373
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After 8 years of followͲup,47.4% of all patientswere alive. This concerned 63.9% of
patientswithatleastaninfraclavicularLNMand46.6%withш10axillaryLNMs(W=0.009)
(Figure5.2b).
InmultivariableCox regressionanalyses, theeffectofhaving ш10axillaryLNMsonOS
was statistically significant (HR 1.46, p=0.042) (Table 5.3). Significant predictors for
decreased OS were the presence of pT3Ͳ4 tumours (HR 1.60, p<0.001) and triple
negative subtype (HR 1.79, p<0.001). Receiving chemotherapy (HR 0.42, p<0.001),






DFS of 67.3%. Compared to patients with pN3a based on infraclavicular LNM (DFS
63.8%) thiswasnot statistically significant (p=0.661) (Appendix5.1a). Inmultivariable
Coxregressionanalyses,theeffectofhavingpN3abasedoninfraclavicularLNMonDFS
remainedcomparabletopN2a(HR1.17,p=0.491)(Appendix5.2a).
After 8 years of followͲup, 65.5% of pN2a patientswere alive. Again,whichwas not
differentcomparedtoOSofpatientswithpN3abasedoninfraclavicularLNM(OS63.9%)
(p=0.500)(Appendix5.1b).InmultivariableCoxregressionanalyses,theeffectofhaving
















Age(peryearincrement) 1.02(1.02–1.03) <0.001 Ͳ Ͳ
pTͲstageT3Ͳ4vs.T0Ͳ2 1.65(1.39–1.96) <0.001 Ͳ Ͳ
Tumourgrade3vs.1Ͳ2 1.45(1.24–1.69) <0.001 Ͳ Ͳ
TriplenegativesubtypeYesvs.No 2.43(2.01–2.94) <0.001 2.57(2.13–3.11) <0.001
ChemotherapyYesvs.No 0.49(0.42–0.58) <0.001 0.51(0.43–0.60) <0.001
TrastuzumabYesvs.No 0.74(0.59–0.92) 0.007 Ͳ Ͳ
EndocrinetherapyYesvs.No 0.50(0.43–0.59) <0.001 Ͳ Ͳ

















Age(peryearincrement) 1.03(1.03–1.04) <0.001 Ͳ Ͳ
pTͲstageT3Ͳ4vsT0Ͳ2 1.56(1.35–1.79) <0.001 1.60(1.39–1.85) <0.001
Tumourgrade3vs1Ͳ2 1.43(1.26–1.63) <0.001 Ͳ Ͳ
TriplenegativesubtypeYesvsNo 2.38(2.03–2.80) <0.001 1.79(1.47–2.19) <0.001
ChemotherapyYesvsNo 0.42(0.36–0.48) <0.001 0.42(0.36–0.48) <0.001
TrastuzumabYesvsNo 0.64(0.53–0.78) <0.001 Ͳ Ͳ
EndocrinetherapyYesvsNo 0.51(0.45–0.58) <0.001 0.60(0.51–0.71) <0.001








Accordingto thesixthandseventheditionof theTNMclassification forbreastcancer,
pathologicnodalstatusisdefinedusingthenumberandlocationofLNMs.ApN3astatus
in breast cancer consists either of at least an infraclavicular (level III) or ш10 axillary
LNMs.7 Inclusion of both groups in the same category of TNM suggests a similar
prognosis.8,9,13However,ourstudydemonstratedsuperiorDFSandOS inpatientswith









defined according to final pathological report, resulting in pathologically confirmed
infraclavicular LNM inall83patientsand therefore representingamore validpatient
population.
ClassificationofinfraclavicularLNMaspN3adisregardsthenumberofnodalmetastases
and the size of the largestmetastasis. A singlemicrometastasis in an infraclavicular
lymph node would represent pN3a status, whereas pN3a without infraclavicular
involvementwouldrequireш10LNMswithat leastonemacrometastasis.7Disregarding
size of the nodalmetastases by only taking infraclavicular location into account can
explain part of the difference in DFS and OS between pN3a based on at least an
infraclavicularLNMandш10axillaryLNMs.
DFSafter5yearsinpatientswithш10axillaryLNMsinourstudycohortiscomparableto
previous results of Koca et al., inwhich 5Ͳyear DFSwas 46.2% in patientswith ш10
axillary LNMs.15 In a similar cohort of patientswith ш10 axillary LNMs, Turker et al.
demonstratedthehighest5ͲyearDFSrateof49.2% inpatientswithER/PRþandHer2Ͳ





suspicious nodes located behind the pectoralisminormuscle (level II).17However, in








were detected during physical examination and/or surgery. In the current era, with
imagingmodalitieslikebreastmagneticresonanceimaging(MRI)andpositronͲemission
tomography/computed tomography (PET/CT), smaller (infraclavicular) LNMs can be
detectedprior tosurgery.18,19However, theseventheditionofTNM isstillbasedona
2001study inwhich infraclavicularLNMsweredetectedwithphysicalexaminationand
ultrasound rather thanMRI or PETͲCT.2,6Our cohort consisted of patients diagnosed
between2005and2008,whichismoreinlinewiththecurrentimagingmodalities.MRI
wasalready recommended inourstudycohortaccording to thenationalguidelinesof
2005.7,10
AlthoughtheincidenceofpatientswithpN3abasedonatleastaninfraclavicularLNMin
our cohort is small (4.6%), our findings suggest that reclassification in the next TNM
classification should be considered.We advise to redefine an infraclavicular LNM as
equivalenttootheraxillaryLNMsratherthantakingthe locationof infraclavicularLNM
intoaccount.Consequently,patientswithan infraclavicularLNMwithч9LNMswillbe
considered pN2a rather than pN3a. In this way, infraclavicular LNM will become
consistentwithintramammaryandinterpectoralLNM,whicharecodedasaxillaryLNMs
(level I/II) in the current TNM classification.7 Yet, adjuvant (radiation) therapy of
infraclavicularLNMisstillrecommended.
This study had limitations.Amajor limitation of this study concerns the subgroup of
patientswithш10axillaryLNMs,whichstillmighthave infraclavicularLNMaswell.Yet,
the focusof this studywas tocompareprognosisbetweenboth subgroups, since the
current TNM atlas considers both as one category. Our results should therefore be
interpretedwiththisimportantlimitationinmind.
Asecondlimitationofthisstudywastheuseofaretrospectivedatabase.Someclinically
relevant parameterswere not present, for instance, radiation therapy fields and the




Third, thesedataonly containpatients treated in theNetherlandsbetween2005and
2008.Thismighthaveinfluenceonprognosiswhenthesedatawouldbeextrapolatedto






Fourth, despite the collection of nationwide data between 2005 and 2008 in the
Netherlands, the subgroup of patientswith pN3a based on at least an infraclavicular
LNM remained small (n=83). As a consequence, the number of variables for
multivariable Cox proportional hazards regression was restricted due to the limited
numberofevents.12However,differencesbetweenboth subgroups regarding tumour
subtypesandadjuvant treatmentwere small,whichmeans that it isunlikely that the











presentationof results,malignant tumorsof thebreast and larynx.Paris: InternationalUnionAgainst
Cancer;1958.
2. SingletarySE,GreeneFL,BreastTaskF.Revisionofbreastcancerstaging: the6theditionof theTNM
classification.SeminSurgOncol2003;21:53Ͳ59.
3. SobinLH,Fleming ID.TNMclassificationofmalignanttumors,fifthedition(1997).Union Internationale
ContreleCancerandtheAmericanJointCommitteeonCancer.Cancer1997;80:1803Ͳ1804.
4. BeenkenSW,UristMM,ZhangY,DesmondR,KrontirasH,MedinaH,etal.Axillary lymphnodestatus,













10. CBO Kwaliteitsinstituut voor de Gezondheidszorg. Vereniging van Integrale Kankercentra. Guideline
‘Treatmentofbreastcancer’(Richtlijn‘BehandelingvanhetMammacarcinoom’).2005.
11. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc
1958;53:457Ͳ481.
12. VittinghoffE,McCullochCE.Relaxingtheruleofteneventspervariable in logisticandCoxregression.
AmJEpidemiol2007;165:710Ͳ718.









17. American Society of Breast Surgeons. Performance and Practice guidelines for axillary lymph node




axillary lymph node imaging in breast cancer patients: a systematic review. Insights Imaging 2015;6:
203Ͳ215.
19. Koolen BB, Valdes Olmos RA, VogelWV, Vrancken PeetersMJ, Rodenhuis S, Rutgers EJ, et al. PreͲ
chemotherapy18FͲFDGPET/CTupstagesnodalstage instage IIͲIIIbreastcancerpatients treatedwith
neoadjuvantchemotherapy.BreastCancerResTreat2013;141:249Ͳ254.
20. SenkusE,KyriakidesS,OhnoS,PenaultͲLlorcaF,PoortmansP,RutgersE,etal.Primarybreastcancer:







22. AllemaniC,WeirHK,CarreiraH,HarewoodR, SpikaD,WangXS, et al.Global surveillanceof cancer
































LNM 58 57 49 45 37 23


























LNM 83 81 73 68 63 61 56 26 12
ш10axillary


















Age(peryearincrement) 1.03(1.02–1.03) <0.001 Ͳ Ͳ
pTͲstageT3Ͳ4vsT0Ͳ2 1.94(1.64–2.31) <0.001 Ͳ Ͳ
Tumourgrade3vs1Ͳ2 1.65(1.44–1.88) <0.001 Ͳ Ͳ
TriplenegativesubtypeYesvsNo 2.92(2.47–3.46) <0.001 3.08(2.60–3.65) <0.001
ChemotherapyYesvsNo 0.41(0.35–0.47) <0.001 0.44(0.38–0.51) <0.001
TrastuzumabYesvsNo 0.72(0.59–0.88) 0.001 Ͳ Ͳ
EndocrinetherapyYesvsNo 0.42(0.36–0.48) <0.001 Ͳ Ͳ
















Age(peryearincrement) 1.04(1.04–1.05) <0.001 Ͳ Ͳ
pTͲstageT3Ͳ4vsT0Ͳ2 1.88(1.64–2.18) <0.001 1.82(1.58–2.10) <0.001
Tumourgrade3vs1Ͳ2 1.50(1.34–1.68) <0.001 Ͳ Ͳ
TriplenegativesubtypeYesvsNo 2.68(2.32–3.10) <0.001 1.75(1.47–2.10) <0.001
ChemotherapyYesvsNo 0.31(0.28–0.35) <0.001 0.34(0.30–0.38) <0.001
TrastuzumabYesvsNo 0.62(0.52–0.74) <0.001 Ͳ Ͳ
EndocrinetherapyYesvsNo 0.44(0.39–0.49) <0.001 0.51(0.45–0.59) <0.001





































































From the Netherlands Cancer Registry, including data from all hospitals in the
Netherlands,allnew invasiveepithelialbreastcancers (M0) treatedwithmastectomy,
diagnosed in2005Ͳ2008were included.Endpointswere incidenceofandpredictorsfor





29.8%,chemotherapy in45.9%,endocrine therapy in69%ofER+and trastuzumab (in
Her2+ tumors) in58.3%.Overall,5ͲyearLRasa firsteventoccurred in3.8%.Thiswas






(versus 1Ͳ3, HR 2.29[1.63Ͳ3.21]) and T4Ͳstage (versus T0Ͳ1, HR 5.50[3.05Ͳ8.38]). The




Currently, particularly triple negative tumors are at risk for LR after mastectomy.
Commonly known risk factors (numberofpositivenodes, T4Ͳstage, andnoendocrine
therapy) were confirmed, but their importance varied between subtypes. Local






The incidence of local recurrence (LR) aftermastectomy has decreased over the last
decades, resulting from better diagnostics, surgery, radiotherapy, and systemic




(PMRT). This estimate isbasedon traditional risk factors, such asnodal stage, tumor
stage, lymphovascular invasion (LVI), tumor grade, and age.1Ͳ3 The recommendations
basedonnodalstagearewidelyusedandbasedmainlyontheEBCTCGmetaͲanalyses.
First,the indicationwasestablishedforhighriskpatients, i.e.with>3positivenodesor
>T3 tumors, and later also for intermediate risk patients (1Ͳ3 involved nodes, or T2




absence of screening and no or suboptimal systemic therapy compared to nowadays
(CMF insteadofantracyclinesandtaxanes;notrastuzumab).Also,radiationtechniques
andplanninghaveimproved(e.g.,3Dinsteadof2Dtechniques).Finally,radiationfields
varied between the trials and were generally more extensive (including the axilla,
supraclavicular fossa and internalmammary chain) thanmany clinicswould currently
use.Thesedifferences in incidenceandpatientmanagementmayall impacttheriskof




(e.g. TͲstage and NͲstage) to a tumor biology based approach (intrinsic subtypes,
molecular profiling). It is conceivable that different subtypes of breast cancer pose
different risks for LRaftermastectomy,anddifferentabsoluteand/or relativebenefit
from radiation therapy.Severalstudieshaveaddressed riskofLRaftermastectomy in
subtypesofbreastcancer, somealso includingHer2 status.7Ͳ9However, these studied








This study aims to determine 5Ͳyear risk of LR as a first event aftermastectomy in
different breast cancer subtypes, treated in the current era. Additionally, it aims to






Netherlands. Trained datamanagers of the Comprehensive Cancer Organisation the
Netherlands (IKNL) gather data from patients’ records. The database includes patient
and tumorcharacteristics,aswellassurgical,radiation,andsystemic treatment.Fora
period of 5 years after diagnosis, the first breast cancer event was registered (LR,
contralateralbreastcancer,regionalrecurrence,ordistantrecurrence).
Includedpatients





regional treatment consisted of sentinel lymph node biopsy (SLNB) in clinically node
negativebreastcancer,basedonphysicalexamination(axillaryultrasoundwascommon
butnotmandatory).ContraindicationsforSLNBwere>T2,multipletumors,andprevious
axillary surgery. If positive nodes were identified preoperatively, or SLNB was
contraindicated, or SLNB was positive, axillary lymph node dissection (ALND) was
performed.Chestwall irradiationwas recommended forpositivemargins, T4 tumors,
involvementof thepectoralismuscle,andwasconsidered individually forpT3 tumors.
Chestwall irradiation including regional nodal fieldswas applied in case of шpN2 or
involvement of upper medial axillary nodes. Recommended dose was 45Ͳ50Gy in
5weeks,andboostto60Ͳ70Gyincaseofresidualtumor.
Indication for systemic treatment depended on nodal involvement, age, tumor size,
grade,andreceptorstatus. InN+breastcancer,endocrinetherapywasrecommended




premenopausal women, and in women <69 years with ERͲ and PRͲ tumors. In
postmenopausalwomenaged50Ͳ59withER+PR+ andN+ tumors, chemotherapywas













Five different subtypes of breast cancerwere studied, namely ER+PR+Her2Ͳ, ER+PRͲ
Her2Ͳ,ER+Her2+,ERͲHer2+,and triplenegative tumors.Tumorswere consideredER+
and PR+ if more than 10% of tumor cells showed nuclear staining on
immunohistochemistry (IHC).Her2statuswasevaluatedwithat least IHC, inwhich3+
was considered positive (>10% of cells show circumferentialmembrane stainingwith
strong intensity) and0 and1+negative (<10% circumferentialmembrane staining,or
>10%membranestainingbutweakintensity).Incaseof2+onIHC(>10%circumferential
membrane staining with moderate intensity), the guideline advised FISH for
confirmation. The result of FISH overruled the result of IHC. If subtype could not be
determined,thecasewasdisregardedforallsubtypeanalyses.
Endpoints
The primary endpointwas LR as a first eventwithin 5 years after diagnosis. LRwas
defined as any invasive breast cancer on the ipsilateral thoracic wall including the
mastectomyscar,i.e.bothLRandnewprimaryipsilateralbreastcancerwerecounted.12
Eventsoccurring0Ͳ91daysafterdiagnosiswere regarded synchronous to theoriginal
tumorandnotcountedasrecurrences.Patientswerecensoredatthedateoftheirfirst
event,atthedateof last followup,oratthedateofdeath. Ifanothereventoccurred





Analyseswereperformedusing SPSS [IBMCorporation, version22/23.0.0.0] andR [R
foundation,version3.3.2].LR incidencewasdetermined for thewholecohortand the




analysis. Theproportional hazards assumptionwas tested by visual inspection of logͲ
minusͲlogplots. Incaseofdoubt,scaledSchoenfeldresidualswerecalculatedand the
proportional hazards assumption was tested by assessing the correlation of the
Schoenfeldresidualswithtime.Aslopedifferent fromzero indicatesaviolationofthe





equivocal). Subtype could not be determined in 13.7% (n=2106). PRMT was






for ER+PR+Her2Ͳ tumors (2.8%) and highest for triple negative tumors (9.5%). The
overalldifferencebetweenthesubtypeswasstatisticallysignificant (LogRank (MantelͲ
Cox) test,ChiͲsquare (4)=166.039,p<0.001).UnivariableCox regressionwasused to
compare subtypes to the most favorable subtype. Compared to ER+PR+Her2Ͳ, no
significant difference existed for ER+PRͲHer2Ͳ tumors (HR 1.155 [95%CI 0.839Ͳ1.589],







 N(%)  N(%)
Medianage
(range)
 59.0(20Ͳ100) Ductal 10750(69.9%)







T3 992(6.4%) No 14542(94.5%)
T4 312(2.0%) Microscopic 559(3.6%)
pTͲstage
Tx 398(2.6%) Macroscopic 33(0.2%)








N3 1102(7.2%) Yes 7057(45.9%)
pNͲstage

















Unknown 226(1.5%) ER+PR+Her2Ͳ 7296(47.4%)
Positive 9182(59.7%) ER+PRͲHer2Ͳ 1822(11.8%)
Negative 5383(35.0%) ER+Her2+ 1364(8.9%)
PR
Unknown 817(5.3%) ERͲHer2+ 1198(7.8%)










Table6.2 Local recurrence as a first event overall and in subtypes and hazard ratio compared to
ER+PR+Her2ͲonunivariableCoxregression
 N= 5ͲyearLRasafirstevent HR(95%CI) pͲvalue
Total/overall 15382 3.8%  
ER+PR+Her2Ͳ 7296 2.8% ZĞĨ 
ER+PRͲHer2Ͳ 1822 3.1% 1.155(0.839Ͳ1.589) 0.377
ER+Her2+ 1364 3.0% 1.096(0.766Ͳ1.569) 0.616
ERͲHer2+ 1198 4.7% 1.863(1.357Ͳ2.558) <0.001




























Of 1364 ER+Her2+ tumors and 1198 ERͲHer2+ tumors, 853 (62.5%) and 857 (71.5%)
weretreatedwithchemotherapy,and751(55%)and745(62.2%)withtrastuzumab. If
chemotherapy was administered (suggesting that trastuzumab was also indicated),
86.9%ofER+Her2+and86.6%ofERͲHer2+ tumorsalso received trastuzumab.LRasa
firsteventoccurredin2.5%ofER+Her2+and4.7%ofERͲHer2+tumors(Table6.3).The
incidenceofLRwassignificantly lower inpatientstreatedwithbothchemotherapyand
trastuzumab than treatment with chemotherapy alone (2.0% vs. 6.0% in ER+Her2+,
p=0.020; and 3.5% vs 6.9% in ERͲHer2+, p=0.047). The group treated without
chemotherapy and trastuzumab is heterogeneous (either no indication or





Table6.3 Local recurrence as a first event in ER+Her2+ and ERͲHer2+ patients with and without
trastuzumab
 ER+Her2+ 5ͲyearLRas1stevent ERͲHer2+ 5ͲyearLRas1stevent
Chemotherapy+trastuzumab 741(54.3%) 2.0%* 742(61.9%) 3.5%#
Chemotherapyonly 112(8.2%) 6.0%* 115(9.6%) 6.9%#
dƌĂƐƚƵǌƵŵĂďŽŶůǇ ϭϬ;Ϭ͘ϳйͿ ϭϰ͘ϯй;ŶсϭͿ ϯ;Ϭ͘ϯйͿ Ϭй
EŽĐŚĞŵŽƚŚĞƌĂƉǇͬƚƌĂƐƚƵǌƵŵĂď ϱϬϭ;ϯϲ͘ϳйͿ ϯ͘ϲй ϯϯϴ;Ϯϴ͘ϮйͿ ϲ͘ϵй
Total 1364 2.5% 1198 4.7%




To assess predictors for LR after mastectomy, several factors were analyzed using
univariable (SupplementTable S6.2) andmultivariableCox regression (Table6.4).The
proportional hazards assumption was met for all but two variables included in the
multivariablemodel,namelyendocrinetherapyandgrade.
In the overall population, most factors were significantly associated with LR. The







The strongest independentpredictors for LRonmultivariableanalysis variedbetween






0.28 [0.09Ͳ0.91]),endocrine therapy (protective,HR0.34 [0.16Ͳ0.75]),andnopositive
nodes(protectivevs.1Ͳ3nodes,HR0.31[0.14Ͳ0.67]).




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































compared to T0Ͳ1 (higher risk, HR 3.41[1.67Ͳ6.96]) and T4 tumor compared to T0Ͳ1





Some predictors had different effects in different subtypes. PMRT was significantly
protective inallsubtypes,exceptforHer2+subtypes,whichshowedHRsaround1and
broadconfidenceintervals.ThisreflectslittleornoeffectonLRand/orlackofprecision







More affected nodes were associated with significantly more LR in the overall
population.However,ER+PR+Her2Ͳ tumorswith1Ͳ3positivenodesdidnothavemore
LRsthanpatientswithoutpositivenodes. Incontrast, intriplenegativebreastcancers,
the number of affected nodes was a strong predictor for LR on this multivariable
analysis.Grade3wasassociatedwithan increasedriskofLR in theoverallpopulation
andER+PR+Her2Ͳtumors,butwasnotsignificantintheothersubtypes.
Discussion
This study of 15382 breast cancers treated withmastectomy in The Netherlands in
2005Ͳ2008,showedthatLRasafirsteventwithin5yearsaftermastectomyoccurredin
3.8%. The incidence varied between subtypes; fewest LR occurred in ER+PR+Her2Ͳ
(2.8%) andmost in triple negative tumors (9.5%). Significantly fewer LRs occurred in
patients with Her2+ tumors treated with both chemotherapy and trastuzumab than
patientstreatedwithchemotherapyalone(2.0%vs.6.0%inER+Her2+;3.5%vs.6.9%in
ERͲHer2+).Thestrongest independentpredictors forLR intheoverallpopulationwere
endocrinetherapy(protective),>3positivelymphnodes,andT4Ͳstage.Theimportance




Some of the findings suggest that current guidelines regardingmore aggressive local
therapy, based on traditional characteristics without considering subtype, may be
inappropriate.Her2+tumorshadfewerLRsthandescribed inearlierpublications13and







elucidated. In this study, theprotectiveeffectofPMRTwas significant inall subtypes
exceptHer2+ tumors, after correction for trastuzumab.Resistance to radiotherapy in
Her2+ tumors has been described, e.g. in a postͲhoc review of the Danish trials13,
conducted before introduction of trastuzumab. This showed that generally Her2+
tumorsdidnothave fewerLRRafterPMRT,althoughERͲHer2+ tumorsdid.Further,a
recent study found a nonͲsignificant reduction in LRR after PMRT for Her2+ tumors
treatedwithout trastuzumab, no LRRswere seenwhen both trastuzumab and PMRT
were used.17Another retrospective analysis of two cohorts treatedwith andwithout
trastuzumab14showedthattrastuzumabreducedLRRinwomenreceivingPMRTbutnot
inwomen not receiving PMRT. These studieswere limited by few events and small
patient numbers receiving each combination of treatments (PMRT+trastuzumab,
trastuzumabonly,PMRTonly).This limitsvalidestimationofany interactionbetween
Her2, trastuzumab, and radiosensitivity. A preclinical study18 showed DNA repair in
Her2+ tumorsafter radiation,butadditionofaHer2antibodydiminishedDNA repair,
thuspotentiallyincreasingtheeffectofradiation.ThepreciseinteractionbetweenHer2
overexpression, trastuzumab, and radiation is unclear, although earlier publications
suggest radioresistance of Her2+ tumors (without trastuzumab) and potentially
increasedradiosensitivitybytrastuzumab.

Furthermore, this study suggests that1Ͳ3affectednodes isnota risk factor for LR in
ER+PR+Her2Ͳ tumors, but it is in triple negative tumors.Having 1Ͳ3 positive nodes is
oftenconsideredasignof intermediateLRrisk.Theseresultsshowthat“intermediate
risk”may not be the same for all patients,which is importantwhen identifying risk
groups. Additionally, younger age was not consistently associated with more LRs.






Astrengthofthisstudy isthe largepatientnumber inthiscomprehensive,nationwide
database.Manydatabasesare toosmall toperformmultivariableanalysis,particularly
withinsubtypesofbreastcancer.
Aweakness is potential indication bias. For example,more positive nodesmight be
associated with more LR, but is also an indication for PMRT. This makes etiologic
interpretation of HRs difficult. Indication bias is partly overcome by including most
indications for therapy in themultivariablemodel.Secondly, theproportionalhazards
assumptionheld forallvariablesexceptendocrine therapyandgrade, inmultivariable
analysis of the overall group. As a result, the HR estimates may be somewhat
conservative.19As estimating timeͲdependency of risk factors was not a goal of this
study, we did not replicate the modeling including time dependent covariates.
Additionally, informationonLVIwasnotavailable,norwasKi67.7,8Further,more than
fiveyearsfollowͲupmightbenecessaryforER+tumors,astheseareassociatedwithlate
recurrences,8 although the effect of Her2 status, targeted treatment, modern
chemotherapy,andendocrinetreatmenton laterecurrences isunknown. Inthisstudy,
the KaplanͲMeier curve showed a constant rate of LR until 5 years for ER+ tumors.
Finally,even inthis largedatabase,thenumberofeventswassmall insomesubtypes,
limiting theprecisionof themodel inER+PRͲHer2Ͳ,ER+Her2+, andERͲHER2+ tumors.
This illustrates that current LR rates are low, and that assessing risk factors and
treatmentbenefitinlesscommonsubtypesisdifficult,aseveninverylargecohorts,few




lowerthan intheolderstudies included intheEBCTCGmetaͲanalysis,even inhighͲrisk
subtypes͘5Alowerabsoluteriskwiththesamereductionimplieslowerabsolutebenefit.
Thismeans that theabsolutebenefitofPMRTmightbe small,especially in lowerͲrisk
subtypes.Secondly,althoughahighriskinaretrospectiveanalysisdoesnotprovethata
subtype would benefit from more aggressive treatment, the differences between
subtypesshouldbeconsideredinrandomisedstudiesinvestigatinglocaltreatment,such
the SUPREMOͲtrial20, investigating PMRT in intermediate risk patients. Based on the
currentstudy, it is likely that thedefinitionof intermediate riskdifferspersubtype, in
addition to varying radiosensitivity and benefit from systemic treatment. Trials
investigating localtreatmentshouldreportresultsseparatelyforsubtypes.Becausethe






In conclusion, the overall risk of LR as a first event aftermastectomywas 3.2% and
significantlydifferedbetweensubtypesofbreastcancer.Triplenegativetumorswereat
highest risk and ER+PR+Her2Ͳ at the lowest. Commonly known risk factors were
confirmed,but their importance variedbetween subtypes.Basedon varying absolute
risk, risk factors,andpotentiallydifferent treatmentsensitivity, local treatmentshould
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 ER+PR+Her2Ͳ ER+PRͲHer2Ͳ ER+Her2+ ERͲHer2+ Triplenegative
 7296 1822 1364 1198 1596
Radiationtherapy 1983(27.2%) 559(30.7%) 473(34.7%) 500(41.7%) 566(35.5%)
Chemotherapy 2952(40.5%) 694(38.1%) 853(62.5%) 857(71.5%) 1026(64.3%)
Endocrinetherapy 5042(69.1%) 1272(69.8%) 1083(79.4%) 87(7.3%) 59(3.7%)




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































After treatment for breast cancer, followͲup consists of physical examination and







TheNetherlands Cancer Registry contains data of all newly diagnosed cancers in the
Netherlands. All new epithelial breast cancers without distantmetastasis, diagnosed
between 2005 and 2008 were included. LR risk was calculated with KaplanͲMeier






occurred in 3.0%. This risk varied for different subtypes and was highest for triple
negative (6.8%)and lowest forER+PR+Her2Ͳ (2.2%)tumors.After1,2,3,and4eventͲ








The riskof5Ͳyear LRasa firsteventwas lowoverall (3.0%).This riskdecreasedeven
furtherwith thenumberofeventͲfreeyears.After3eventͲfreeyears, theoverall risk
was1%.ThisimprovementinprognosisisreassuringtopatientsduringfollowͲup.Italso
suggeststhat followͲupbeyond3yearsmayhavea lowyieldofLR,both for individual







from the timeofbreast cancerdiagnosis.However,as timeprogresses and apatient
remains eventͲfree, this initial estimate of local recurrence (or other outcomes)may
have improved. EventͲfree time is usually not considered as a prognostic factor. An
estimate of prognosis that takes the recurrenceͲfree interval into account is called
conditionalsurvivalorrecurrence.
Earlier publications have addressed conditional overall and diseaseͲfree survival in
breast cancer patients,1Ͳ3 howeverwithout focus on local recurrence. Further, these
studieswerebasedonoldercohortsthatdifferedfromcurrentbreastcancerpatientsin
severalways:worsebaselineprognosis,diagnosis inatimeperiodwhenbreastcancer
screeningwasunavailable, incomplete informationon intrinsicsubtypes includingHer2




Furthermore, this information canalsohelp todetermine theoptimal followͲup time,
both for everyday practice and clinical research. After treatment for breast cancer,
followͲup consists of physical examination andmammography for at least five years.
Thereafter, recommendations vary with regard to frequency, duration, and required
investigations.One of the goals of followͲup is to detect possible local and regional
recurrences.4Ͳ7 Information on conditional local recurrence riskmay be used to tailor
followͲupto individualneeds.Althoughextended followͲupmaybedesirable forother
goals suchasmonitoringendocrine therapy and reassurance, a low chanceofevents
may be a reason to shorten followͲup in specific cases. Safely tailoring followͲup to
individual patients could improve quality of care by reducing the number of hospital
visitsandstress.Itcanalsosavehealthcarecosts,andmayalsodecreasetherequired
timeandfinancialresourcesforclinicaltrials iffollowͲupcanbeshortened. Inorderto
preserve quality of care,we need to explorewhich patientsmay be eligible for this
approach.
Earlier studies on conditional overall and diseaseͲfree survival demonstrated the
greatestimprovementofprognosis(inotherwords:greatestreductionofthechanceof

















The Netherlands Cancer Registry (NCR) collects data on all newly diagnosed cancer
patientsinallhospitalsintheNetherlandsfrom1989onward.Fortheyears2005Ͳ2008,
bothfiveͲyearfollowͲuponrecurrencesand informationonHer2statusandtreatment























was assessed with sentinel lymph node biopsy (SLNB) for clinically node negative
patients according to physical examination and biopsy/fine needle aspiration. Axillary
ultrasoundwas common but notmandatory. Contraindications for SLNB at that time
weremultipletumors,>T2,andpreviousaxillarysurgery.IfSLNBwascontraindicated,or
if positive lymph nodeswere identified either preoperatively or by SLNB, an axillary
lymphnodedissection(ALND)wasperformed.

The indication for systemic treatment depended on nodal involvement, tumor size,
grade, receptor status, and age. In N+ breast cancer, endocrine therapy was
recommendedforallpatientswithER+and/orPR+tumors.Chemotherapywasadvised
forN+breastcancerinallpremenopausalwomenandinwomen<70yearsoldwithERͲ




ER+orPR+ tumorsandchemotherapy forERͲPRͲ tumors)wasconsidered forpatients
ч35years(exceptgradeItumorsч1cm),andforpatients>35yearswithtumorsш3cm,
or ш1cm and grade III, or ш2cm and grade II. Standard chemotherapy consisted of
5courses of FEC (fluorouracil/epirubicin/cyclophosphamide) or 6 courses of TAC
(docetaxel/doxorubicin/cyclophosphamide). If chemotherapywas indicated for aHer2
overexpressing tumor, patients were treated with trastuzumab for one year after
chemotherapy.
Endocrine therapy consisted of tamoxifen for 5 years for premenopausal women,
optionally including LHRH agonist if not postmenopausal after chemotherapy. For




ER+Her2+,ERͲHer2+,and triplenegative tumours.Tumourswere consideredER+and
PR+ifmorethan10%oftumourcellsshowednuclearstainingonimmunohistochemistry
(IHC).Her2statuswasevaluatedwithat leastIHC, inwhich3+wasconsideredpositive
(>10%of cellswith strong intensity circumferentialmembrane staining)and0and1+
wereconsiderednegative(<10%circumferentialmembranestaining,or>10%withweak
intensity membrane staining). In case of a 2+ IHC score (>10% circumferential
membrane stainingwithmoderate intensity), fluorescence in situ hybridization (FISH)
Chapter7
122




LRwas defined as any invasive breast cancer in the ipsilateral breast (including skin,
biopsy tract and surgical scar) or on the ipsilateral thoracic wall including the
mastectomyscar,i.e.bothLRandnewprimaryipsilateralbreastcancerwerecountedas
LR.16Eventsbetween0and91daysafterdiagnosiswereregardedassynchronouswith
theoriginal tumour.Patientswere censoredat thedateof their firstevent (seedata
collectionabove),atthelastdateoffollowͲup,oratthedateofdeath.Ifanotherevent
occurredwithin91daysof the first recurrence, thiswasconsideredsynchronouswith
thefirstevent,andalsocountedasafirstrecurrence.
Statistical analyses were performed using SPSS [IBM Corporation, version 23.0.0.0].
KaplanͲMeieranalysiswasusedtodetermine5ͲyearLRasa firstevent, fortheoverall
population and separately for five approximate subtypes of breast cancer. To check
whether there was an effect of subtype independent of tumor and treatment
characteristics, multivariable Cox regression was performed. Variables that were







In total, thedatabase contained34.453newbreast cancersdiagnosedbetween2005
and2008,ofwhich5Ͳyear followͲupwasavailable.Medianagewas59.0years [range:
20Ͳ100]. Of these patients, 15.382 (44.6%) were treated with mastectomy, 19.071
(55.4%) with breast conserving therapy. The majority of tumors were ER+PR+Her2Ͳ







Medianage(range)  59.0[20Ͳ100] Ductal 25833(75.0%)







T3 1036(3.0%) No 32504(94.3%)
T4 343(1.0%) Microscopic 1398(4.1%)
pTͲstage













1 7449(21.6%) Yes 13392(38.9%)




















Unknown 511(1.5%) ER+PR+Her2Ͳ 17770(51.6%)
Positive 21750(63.1%) ER+PRͲHer2Ͳ 3930(11.4%)
Negative 10960(31.8%) ER+Her2+ 2689(7.8%)
PR
Unknown 1743(5.1%) ERͲHer2+ 1897(5.5%)




Negative 26693(77.4%)   
Her2
Unknown 2030(5.9%) Total  34453
ER:estrogenreceptor,PR:progesteronereceptor,BCT:breastconservingtherapy.*IfapatientwithaHer2+




The incidence of LR as a first eventwithin 5 years of diagnosis varied between the
subtypesofbreastcancer(Table7.2,Figure7.1).Incidencewashighestintriplenegative
tumors (5.6%)and lowest inER+PR+Her2Ͳ tumors (1.9%).Thedifferencebetween the
subtypeswas significant,except for thedifferencebetweenER+PR+Her2Ͳ andER+PRͲ
Her2Ͳ (2.2% vs. 2.4%, p=0.329); and ER+PRͲHer2Ͳ and ER+Her2+ (2.4% vs. 2.8%,




Table7.2 Riskof local recurrence as a firstevent (KaplanͲMeier survivalestimates)within5 years after
diagnosisindifferentsubtypesofbreastcancer
 N 5ͲyearriskofLRatdiagnosis Significanceofdifferencebetweenthe
KaplanͲMeiercurves










Triplenegative 3619 6.8% 
ER:estrogenreceptor,PR:progesteronereceptor,Her2:Her2Neureceptor.LogRank(MantelͲCox)wasused
tocomparesignificancebetweentheKaplanͲMeiercurves.*ER+Her2+(2.8%)tumorsdidnothavesignificantly



























known prognostic significance and/or univariable analysis. When corrected for the
selected factors using multivariable Cox regression, the difference in LR between
ER+PR+Her2Ͳtumorsandtheothersubtypeswasstillsignificant(pͲvalues<0.05,HRs,CIs
and pͲvalues in Table 7.3), except for the difference between ER+PR+Her2Ͳ versus
ER+PRͲHer2Ͳwhichhas aHRof0.954withp=0.329.Additionally, after correction for
thesefactors,therewasnolongerasignificantdifferenceinLRbetweenpatientstreated
with mastectomy and breast conserving therapy (HR 1.234, 95% CI 0.944Ͳ1.614,
p=0.124).

Table7.3 Multivariable Cox regression to assess the impact of breast cancer subtype on 5Ͳyear local
recurrenceasafirstevent,correctedforconfoundingfactors
 HR 95%CI pͲvalue
Subtypevs.ER+PR+Her2Ͳ ZĞĨ  
ER+PRͲHer2Ͳ 1.134 0.876Ͳ1.467 0.341
ER+Her2+ 1.535 1.120Ͳ2.105 0.008
ERͲHer2+ 1.525 1.044Ͳ2.228 0.029




































subtype, the riskof LRwithin5 yearsofdiagnosis (theendof regular followͲup)was
calculated(Table7.3).
For the overall group, the risk of developing LR before the end of regular followͲup
(5years)was2.5%.ThisriskdecreasedwitheventͲfreeyears,to2.0%,1.4%,0.9%,and
0.4%after1,2,3,and4eventͲfreeyears(Table7.4).
This decrease in riskwas seen in all subtypes, andwas proportionally largest in the




Table7.4 ImpactofanumberofeventͲfreeyearson the riskof local recurrenceasa firsteventwithin
5yearsafterdiagnosisinsubtypesofbreastcancer












Allpatients 34453 3.0% 2.4% 1.6% 1.0% 0.6%
Approximatesubtypes      
ER+PR+Her2Ͳ 17770 2.2% 2.0% 1.5% 1.0% 0.6%
ER+PRͲHer2Ͳ 3930 2.4% 2.0% 1.4% 0.9% 0.5%
ER+Her2+ 2689 2.8% 2.2% 1.5% 1.0% 0.4%
ERͲHer2+ 1897 4.7% 3.4% 2.0% 0.7% 0.2%
















 Totalno.ofLRs In1styear* In2ndyear In3rdyear In4thyear In5thyear
Allpatients 874(100%) 203(23.2%) 238(27.2%) 186(21.3%) 127(14.5%) 120(13.7%)
Approximatesubtypes      
ER+PR+Her2Ͳ 331(100%) 39(11.8%) 89(26.9%) 77(23.3%) 65(19.6%) 61(18.4%)
ER+PRͲHer2Ͳ 79(100%) 13(16.5%) 23(29.1%) 18(22.8%) 13(16.5%) 12(15.2%)
ER+Her2+ 66(100%) 14(21.2%) 18(27.3%) 12(18.2%) 12(18.2%) 10(15.1%)
ERͲHer2+ 77(100%) 24(31.2%) 24(31.2%) 19(24.7%) 7(9.1%) 3(3.9%)
Triplenegative 203(100%) 81(39.9%) 60(29.6%) 31(15.3%) 14(6.9%) 17(8.4%)
*in1styear:eventswithin3monthsafterinitialdiagnosiswerecountedassynchronoustotheoriginaltumor,







at highest riskwith 6.8% and ER+PR+Her2Ͳ at the lowestwith 2.2%. The difference
(ER+PR+Her2Ͳ compared to the other types) remained significantwhen corrected for
age,TͲstatus,NͲstatus,grade,typeofbreastsurgery,radiationtherapy,chemotherapy,
endocrine therapy,and trastuzumab (exceptER+PR+Her2Ͳcompared toER+PRͲHer2Ͳ).
With increasingnumberofeventͲfreeyears, the riskofhavingaLRbefore theendof
regular5Ͳyear followͲupdecreased.After threeeventͲfreeyears, the riskwas1.0%or
lessinallsubtypesexcepttriplenegativebreastcancer(1.6%).Thedecreaseinthefirst






up, 1 LR can be expected if followͲup is continued until 5 years. This suggests that
although recurrences do occur later in followͲup, 3Ͳyear resultsmay produce similar
resultsto5years,dependingonthesizeofthestudy.
Our results are in linewith publications on breast cancer survival and other cancers,
suggestingthatimprovementwitheventͲfreeyearsisgreatestfortumorswiththeworst
baselineprognosis.8Ͳ11 The results reflect thatERͲ (particularly triplenegative) tumors
show relatively many early LRs (within 2 years), whereas ER+ tumors have a fairly
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constant rate of LRs throughout the 5 years of followͲup. A study investigating
conditional diseaseͲfree survival in relation to subtype also showed that ERͲ tumors




The strength of this approach is the large, nationwide and comprehensive database,
which includes substantial numbers of patients, even of the less common subtypes.
Further,thisstudyprovidesspecificpercentagesofthechanceofLRafteranumberof
eventͲfree years. Although the information on conditional LR can be partly deduced
from the slope of the KaplanͲMeier curve, these exact percentages help using the
informationonthedecliningriskfordeterminingtheuseofcontinuedfollowͲup,bothin
clinical practice and breast cancer research. Limitations of this study are the lack of
followͲupbeyond5years,whichwouldhavebeenusefulespecially forER+ tumors, in
which laterecurrencesareknowntooccur.18Further, inapopulationthatwastreated
according to a guideline, bias by indication will occur. This is partially overcome by
multivariableanalysis.Furthermore,biasby indication is less important in thisproject
compared to other studies, as determining exact estimates of the hazard ratios for
treatment and tumor characteristicswas not an objective of this study. Due to the
inclusionperiod, tumorswere classifiedaccording to the6theditionof theAJCCTNM
classification.This is, in termsofprimarytumorand localrecurrence,thesameas the
current7thedition.14Inthisstudy,nodistinctionwasmadebetween“truerecurrences”





both in clinicalpracticeand forbreast cancer research.First,apatientwhohasbeen
eventͲfree for 3 yearsmay ask about the benefit of continued followͲup visitswith
physical examination and/ormammography to detect LR. FollowͲup visitsmay have
different goals beside detecting local recurrence, including monitoring endocrine
therapy,encouragingitsuse,monitoringandtreatingothersideeffectsofbreastcancer
treatment,evaluationofpsychosocialconcerns,andpatientreassurance.However, for
somepatients,a less than1%chanceof findinga LRmaybea reason todiscontinue
followͲuportailorittoindividualneeds.Nationalguidelinesmayusethisinformationto
allow personalized decisions about the duration of followͲup. Different guidelines





program, continued annual mammograms, no recommendations).4,5,7,20 Of these
guidelines,only theASCO guideline recommends to considerpatientpreferencesand
personal risk,basedonage,specificdiagnosis,and treatmentprotocol.Noneof these














3 years, this riskwas 1% or less in all subtypes except triple negative cancers. This
improvementinprognosisisreassuringtopatientsduringfollowͲup.Italsosuggeststhat
followͲupbeyond3yearsmayhavelimitedyieldwhenitcomestofindingadditionalLR,
both for individual patients and clinical studies using LR as the primary outcome.
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Regional recurrence (RR) is an endpoint in several trials concerning reducing axillary
treatment in cT1Ͳ2N0breast cancerpatients.Topicofdebate regarding these trials is
adequatefollowͲuptime.TheriskofRRmaydecreasewitheachsubsequenteventͲfree












A total of 18,009 cT1Ͳ2N0 (all pN stages) breast cancer patients were included. RR














As a result of several recent (e.g. ACOSOG Z0011, IBCSG 23Ͳ01 and AMAROS)and
ongoing (e.g.BOOG2013Ͳ07,POSNOC, SENOMAC, SINODAR,BOOG2013Ͳ08, SOUND,
INSEMA, and NCT01821768) randomized controlled trials, the extent of axillary
treatment inbreast cancerpatients isbeing reduced.1Ͳ6 Frequentlyusedendpoints in
thesetrialsareregionalrecurrence(RR),diseaseͲfreesurvival(DFS)andoverallsurvival
(OS).Theseendpointsarestandardlyreportedasratesafter5and10ͲyearsoffollowͲup.







This is in accordance to ovarian, colorectal, endometrial, and testicular cancer and
melanoma patients, inwhich prognosis for cancer survivors generally improveswith
eacheventͲfreeyear.10,12,13NopriorstudieshaveassessedconditionalRRamongbreast
cancer patients. It is conceivable that in linewithOS andDFS the risk for RRmight
decreaseaftereventͲfreeyears.
Adequate duration of followͲup in both clinical and research setting remains
controversial. Most studies report their first results after 5 years, but it has been
suggestedthatmostRRsoccurinthefirstyearsafterdiagnosis.Thisquestionstheyield
andthereforeuseoflongerfollowͲupforthispurpose.Anothertopicofdebateinthese

















which data on first breast cancer eventwithin 5 years after diagnosiswas gathered
directly from patient files. First breast cancer event was registered as new primary





of previousmentioned randomized controlled trials, involving breast cancer patients
withaclinicallyT1Ͳ2tumorandclinicallynodenegativestatus.First,theoverallclinically
T1Ͳ2N0 population (consistentwith the study population of BOOG 2013Ͳ08, SOUND,
INSEMAandNCT01821768)wasanalyzed.6Second,patientsfromthispopulationwitha
positive sentinel lymph node (SLN) (consistentwith the study population of ACOSOG
Z0011,IBCSG23Ͳ01,AMAROS,BOOG2013Ͳ07,POSNOC,SENOMACandSINODAR)were
















Adjuvant systemic treatment was recommended for all pN+ breast cancer patients.
AdjuvantsystemictreatmentforN0patientswasrecommendedforpatients<35years
and forpatients ш35 yearswith risk factors.Risk factorswere tumor ш3cm,or tumor
ш1cmandgradeIII,ortumorш2cmandgradeII.Chemotherapyregimenconsistedoffive
courses5Fluorouracil,Epirubicin,Cyclophosphamide (FEC)or sixcoursesofTaxotere,
Adriamycin and Cyclophosphamide (TAC). Endocrine therapy (Tamoxifen and/or
LuteinizinghormoneͲreleasinghormoneagonist)wasrecommendedforER+and/orPR+




5 years after diagnosis, conditional to being eventͲfree for 1, 2, 3, and 4 years. RR
included recurrence in an ipsilateral axillaryͲ, infraclavicularͲ,or supraclavicular lymph
node,internalmammary/parasternalorintramammarylymphnode.15
RR within 91 days following diagnosis was regarded as a synchronous event and
excluded fromanalysis.Patientswerecensoredat thedateof their firstevent,at the
dateoflastfollowͲup,oratthedateofdeath.Ifanothereventoccurredwithin91days









Cox regression was used to determine the effect of subtype corrected for several











22Ͳ98). The most prevalent subtype was ER+PR+Her2Ͳ in 9,929 patients (55.1%),
followed by ER+PRͲHer2Ͳ in 2,032 patients (11.3%), triple negative tumors in 1,701
patients(9.5%),ER+Her2+in1,231patients(6.8%)andERͲHer2+in667patients(3.7%).
Subtypewasunknownin2,449ofthepatients(13.6%).AllpatientsunderwentanSLNB
















































































































Median followͲup timewas58.3months (range0.07Ͳ60.02).The incidenceofRRasa
firsteventwithin5yearsofdiagnosiswas1.3%intheoverallcT1Ͳ2N0group,and1.5%in
the subpopulation of pT1Ͳ2N+(sn) patients. These results were corrected for
confounders, for both the overall cT1Ͳ2N0 group and subpopulation of pT1Ͳ2N+(sn)
(Appendix8.2).After1,2,3 and4eventͲfree years, the riskofdevelopingRR in the
remainingperioddecreasedinbothgroups.IntheoverallcT1Ͳ2N0group,theriskofRR
decreasedwithadditionaleventͲfreeyearsto1.1%,0.8%,0.6%,and0.3%,respectively
(Table8.2). InthepT1Ͳ2N+(sn)subpopulation, theriskofRRdecreased to1.2%,0.8%,


















































































was highest for triple negative (3.7%) and lowest for ER+PR+Her2Ͳ tumors (0.8%)
(Table8.2).ThedifferencebetweenthesubtypesER+PR+Her2ͲandER+PRͲHer2Ͳ (0.8%
vs.1.5%,p=0.001);andbetweenERͲHer2+andtriplenegativeweresignificant(1.8%vs.
























































































The riskofRRasa firsteventwithin5yearsafterdiagnosisdecreased inall subtypes
from both the overall and subgroup,whenmore eventͲfree years had passed. Triple
negative tumors had theworst prognosis at baseline, but showed proportionally the
largestdecrease:3.7% to0.4% in the cT1Ͳ2N0 group, and10.7% to1.2% in thepT1Ͳ
2N+(sn)subgroup.Tumorswiththebestprognosisatbaseline,whichwereER+PR+Her2Ͳ
tumors in the overall cT1Ͳ2N0 group (0.8% to 0.2%), and ER+Her2+ tumors (0.4% to
0.4%) and ER+PR+Her2Ͳ (0.5% to 0.2%) in the pT1Ͳ2N+(sn) subgroup, showed
proportionally the smallest decrease. After 2 eventͲfree years, the overall risk of
developingRRwithin5years,was lessthan1% inthecT1Ͳ2N0groupandpT1Ͳ2N+(sn)
patients(Table8.2and8.3).
Triplenegative tumors in thecT1Ͳ2N0groupachieved this low rateafter3eventͲfree
years.InthesubgroupofpT1Ͳ2N+(sn)patients,theriskofdevelopingRRwithin5years























































Studies of Allemani et al., Arrington et al. and JanssenͲHeijnen et al. showed that
conditional DFS and OS improves as time elapses since breast cancer diagnosis.8,9.11
Furthermore,thestudyofJanssenͲHeijnenetal.showedacleardifferenceinconditional
survivalbetweenstage(favorableforstageIIIversusstageIͲII)andbetweenagegroups
(favorable for age groups 45Ͳ54 and 55Ͳ64 years). These differences in conditional
survivalremainedsignificant,butdecreasedintime.10,11Noneofthesestudiesreported
the impactofsubtypeasaprognosticfactoronconditionalsurvival.Inthecurrentera,




Dutch breast cancer patients diagnosed between 2005 and 2008 were included.
Thereforeallsubtypes, includingER+PR+Her2Ͳ,ER+PRͲHer2Ͳ,ER+Her2+,ERͲHer2+,and
even triplenegative tumorsareadequately represented in thiscohort.Although triple
negativebreast cancerpatientswere less frequentlydiagnosedwithapositiveSLNat
diagnosiscomparedtoothersubtypes,thesetumorshadthehighestriskofRRasafirst
eventwithin 5 years after diagnosis (3.7% in the overall group and 10.7% in the SN
positive subpopulation). The systematic review of Lowery et al. concluded that
locoregionalrecurrencewassignificantlyhigherintriplenegativetumorscomparedwith
other subtypes.16Metzger et al. also observed an increased incidence of RR in triple
negative tumors compared to other subtypes.17 In contrast, van Roozendaal et al.











followͲup iscontinued toat least5yearsafterdiagnosis.However, inonlyoneof the










LateRRdefinedasRRaftermore than5yearsofsurgery,occurred inonly fiveof the
1,529 includedpatients.The recentlypublished10Ͳyear resultsof theACOSOGZ0011
trialshowedthatfrom5to10yearsoffollowͲup,inonlytwopatientsaRRoccurredin
theALNDgroupversusfive intheSLNBalonegroup.20Theseresults implythat lateRR
afteranegativeSLNBisrare.ThequestionremainswhetherthisisalsoapplicabletoER+
tumors treated with at least 5 years of hormone therapy.21,22 Further, this analysis
includesallpatientswithapositiveSLN,i.e.1Ͳ3and4ormore,asonlythetotalnumber
of positive nodes was registered and not the number of positive SLNs.  Another
limitationofthisstudyisthatonlythefirstevent(RR)within5yearsafterdiagnosiswas
registered,whichcouldhaveresulted inanunderestimatednumberofevents.Finally,




Inconclusion,theoverallriskofRRasa firsteventwas low (1.3%).After1,2,3and4
eventͲfreeyears,theriskofRRdecreasedinbothgroupsandallsubtypes.Theabsolute
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Subtype ismissing is in13.6%.Nnumberofcases,ERestrogenreceptor,PRprogesteronereceptor,HER2humanepidermal




















































Ageperyear 0.975 0.961–0.989 0.001 0.992 0.964–1.021 0.591
Grade1Ͳ2vs3 0.443 0.294–0.666 0.000 0.174 0.080–0.380 0.000
BreastsurgerymastectomyvsBCT 0.605 0.302–1.212 0.157 0.382 0.141–1.034 0.058
pTͲstadiumT1vsT2 0.506 0.355–0.719 0.000 0.734 0.408–1.320 0.301
pNͲstadiumN0vsN1 0.400 0.278–0.575 0.000 Ͳ Ͳ Ͳ
pNͲstadiumN1vsN2Ͳ3 Ͳ Ͳ Ͳ 0.536 0.231–1.244 0.146
Radiationtherapynovsyes 2.905 1.464–5.763 0.002 4.129 1.511–11.283 0.006
Chemotherapynovsyes 2.701 1.656–4.405 0.000 2.031 0.864–4.777 0.104
Endocrinetherapynovsyes 2.958 1.837–4.763 0.000 3.999 1.551–10.310 0.004
Trastuzumabnovsyes 1.369 0.579–3.234 0.474 1.973 0.346–11.236 0.444










































disagreedat firstaboutdefinitionsof localand regionalendpoints,but finally reached
consensus onwhatwe should classify as local event, second primary breast cancer,
regionalevent,anddistantevent inbreastcancerstudies.Some issuesweresubjectto
debate as the expert panel considered that the available evidence was insufficient,
namelywhether contralateral lymphnode recurrences aredistantor regionalevents,







of published cases of CLNRwasmore similar to regional events than distant events,
namely82.6%overallsurvivaland65.2%diseaseͲfreesurvivalafteramedianfollowup
of 50months. It also suggested that CLNR alone without any other recurrence has
inferior prognosis compared to CLNR and simultaneous ipsilateral breast tumor
recurrence(IBTR).

Because this review was limited by a small number of patients and a high risk of
publicationbiasand thereforeat riskoverestimationofprognosis,Chapter4explores
prognosis of CLNR in a larger population. It includes data from two national cancer
registries and three individual hospitals. In contrast to the systematic review, this
populationhadOSofonly30.2%after5years.Thiswasworsecomparedtoprognosis
after ipsilateral lymph node recurrences (5Ͳyear OS 57.4%) but better compared to
distantmetastasis (5ͲyearOS10.1%).Thestudywas limitedby the fact that theCLNR




the CLNR. Furthermore, information on both the presence of IBTR, and influence of








similar to presence of >10 affected axillary lymph nodes. This chapter shows that
prognosis of patients staged as pN3a based on infraclavicular nodes is better than
prognosisofpatientsstagedpN3abasedon>10axillarylymphnodes,andsuggeststhat
thenextTNMclassificationshouldnotclassifytheminthesamecategory.
In conclusion, the firstpartof this thesis shows that inbreast cancer research,many




The second part of this thesis focused on individual risk and the timing of local and
regional recurrence.A first step towardsmore individual risk assessment isusing the




Chapter 6 studied the risk of local recurrence after mastectomy in these different
subtypes.Thisstudyshowedthatthesesubtypesareimportant:theirabsoluteriskofLR
varies(triplenegativetumorswereatthehighestrisk),andalsodifferentriskfactorsare
important in different subtypes. Furthermore, other studies have suggested that
differentsubtypesmayresponddifferentlytotreatmentsuchasradiationtherapy.This
meansthatthedecisionwhichpatientsneed localtreatmentsuchasradiationtherapy
should be tailored to subtype, and research investigating local treatment should
describe the results separately for different subtypes of breast cancer sowe can do
betterinthefuture.

Chapter 7 and 8 focus on the timing of local and regional recurrences in different
subtypes of breast cancer.We often express prognosis in terms of 5Ͳyear risks, for









different subtypes showed different patterns of recurrence for both LR and RR: the
subtypeswith thehighest risks (triplenegative andHer2+breast cancer) showed the
fastest decline. This information can be reassuring to individual patients who have
remained event free for anumberof years. It also suggests that followͲupbeyond3
years may have low yield (although recurrences do happen). This is particularly
important for breast cancer research, to estimate whether continued follow up will
change the message of the study. This may lead to acceptance of earlier results,
although longer followͲupmay be necessary for other outcomes and for ER+ breast




In futurebreast cancer research, these findingsmayhaveapositive influenceon the
quality and fast availability of reliable results. Using clear and consistent definitions
throughoutbreastcancerresearchwillfacilitatereliablecomparisonofresults.Tailoring
followͲup to subtypesofbreast cancer isa first step towards reacting to thebiologic
behaviorofthetumor,insteadofaoneͲsizeͲfitsͲallapproach.Thelowabsoluteyield(as
a resultof the lownumberofevents)may lead toevaluating (preliminary)outcomes
after3yearsinsteadof5or10(atleastforlocalendpoints).Thismayspeedupcertain
studiesalthoughitwillcertainlynotbepossibleforeverytrial.
Particularly the low risk of recurrence will be a challenge for future breast cancer
research,asthiswillmake itdifficulttoobtainstatisticallysignificantresults.Thefocus
on statistical significance of the results and the lack ofpowerdue to lownumber of
events,however,sometimesdistractsourattentionfromtheactualsizeofthebenefit.
Lackofpowerbecausenottheexpected5%butonly1%developedarecurrence,does
notmean that the study isof lowquality; itmeans thatboth treatmentswere really
good. Furthermore, a difference between two interventions (even if statistically
significant)maybesosmall,thatwedonotconsideritclinicallyrelevant.Averystriking
examplewastheACOSOGZ11study,1,2randomizingwomenwithcT1Ͳ2N0breastcancer
and 1Ͳ2 positive sentinel nodes after breast conserving therapy to either watchful
waitingoraxillary lymphnodedissection).Thestudywasclosedearlybecauseofslow
accrualandconsequently, itwasunderpoweredandnosignificantdifferencewasseen




median followͲupof6.3 years.Thisdifferencewasnot significant,buthad itbeen, it
would not be clinically relevant and certainly not justify exposing all patients to the
potentialmorbidityofALND.Additionally,othermeaningfuloutcomes suchasOSand
DFSwerealsonotsignificant.Theauthorsconcludedthatalthoughprognosisisinferior
inwomen having 1Ͳ2 positive sentinel nodes (compared towomenwithout affected
sentinel nodes), the axillary lymph node dissection did not improve this prognosis.




















Ibelieve this is the futureofbreast cancer treatment,but these studieswill face the
challengeoflongfollowͲupandloweventrates.Carefullychoosingendpoints,ensuring
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In Hoofdstuk 1 van dit proefschrift blijkt uit een literatuurstudie dat borstkankerͲ







dedefinities van lokale en regionale terugkeer (ookwel recidief) vanborstkanker. Zij
warenheteerstnietoveralledefinitieseens,maaruiteindelijkbereiktenzijconsensus




geïdentificeerd in Hoofdstuk 2. Het komt voor dat borstkanker terugkomt in een
lymfeklieraandeanderezijdedandeborstkanker(duseenlymfeklierindelinkeroksel,






totale overleving van patiëntenmet lymfeklierrecidief aan de andere zijde na 6 jaar





Om die reden hebben we in Hoofdstuk 4 de prognose opnieuw bepaald uit
kankerregistraties(Nederland,Denemarken)enenkeleindividueleziekenhuizen.Hieruit
bleekdatdeprognose van lymfeklierrecidief aande andere zijde slechterwasdan in
162
Hoofdstuk 3 gevonden werd, namelijk 30.2% totale overleving na 5 jaar, en ergens
tussen de prognose van een lymfeklierrecidief aan dezelfde kant (57.4% 5Ͳjaars
overleving) en een uitzaaiing (10.1% 5Ͳjaars overleving) in zat. Ook deze studie had
beperkingen,waaronder ontbrekende gegevens die hadden kunnen helpen verklaren
waaromdeprognosebeterofslechterwasenhet feitdatdegebruiktegegevenswat
ouderwaren.Dezebeperkingenkunnener toe leidendatdeprognose indeze studie
juist onderschatwordt.Hoofdstuk3 en4wijzen erdusop dat de prognose van een
lymfeklierrecidief aan de andere zijde ongunstiger is dan een lymfeklierrecidief aan










met meer dan 10 klieren in de oksel. Die twee groepen behoren dus niet in een
categoriegeclassificeerdteworden.

Kortom, de eerste vijf hoofdstukken laten zien datwe helaas vaak appelsmet peren
vergelijken inborstkankeronderzoekensteltgestandaardiseerdedefinitiesvooromdat
devoorkomen inde toekomst.Daarnaastwordenantwoordengegevenopenkelevan
de discussiepunten over classificatie, waar wetenschappelijke gegevens nog voor
ontbraken.

Het tweededeelvanditproefschrift focustop individueel risicovoor terugkeerende
timingdaarvan.Eeneerstestapomdatrisicobeter in teschatten is tekijkennaarde
receptoren op borstkankercellen. De combinatie van receptoren zegt iets over het
biologisch gedrag van de tumor, bijvoorbeeld agressief of juist relatief gunstig. Deze
receptoren (oestrogeen,progesteronenHER2)bepalenweal jaren routinematigvoor
alle nieuwe borstkankers. Op basis van de combinatie van receptoren delen we de
tumoreninsubtypesin.
Hoofdstuk6kijktnaardekansoplokaalrecidiefnahetverwijderenvandeheleborstbij














diagnose laagwas (3% lokaal recidief en 1.3% regionaal recidief in 5 jaar). De kans
verschiltookhierpersubtypewaarbijdekansverdelingvergelijkbaarismethoofdstuk6:
deminste recidieven tradenopbijdehormoongevoeligeenHer2negatieve tumoren
(2.2% lokaalen0.8% regionaal)endemeestebijde tumorendienegatiefwarenvoor
alledriedereceptoren(6.8%lokaalen3.7%regionaal).Daarnaastbleekdathetrisicoop
lokaal en regionaal recidief afneemtmet de ziektevrije jaren en dat die afname het
snelst is insubtypesmethethoogsterisicobijdiagnose.Na3ziektevrije jarenwasde
kansom inde volgende2 jaarnogeen lokaal recidief te krijgen1%ofminder inalle
subtypes (behalve het ongunstigste type met 1.6%), en de kans om een regionaal
recidieftekrijgenminderdan1%inallesubtypes.
Deze gegevens zijnbelangrijk voor individuelepatiënten,omdatdit geruststelling kan
biedeneneenmeergepersonaliseerdbeeldvanhunprognoseoplevert.Dezeinformatie
kan, incombinatiemetanderegegevensen voorkeuren,eventueelookmeegenomen
worden in de beslissing om controle in het ziekenhuis te verkorten. Ook in
borstkankeronderzoekisdetimingvanhetoptredenvanrecidievenbelangrijk,omdatde
followͲupduurbepaalthoe snelde resultatenbeschikbaar zijnenomdateen langere
duurvaakhogekostenmetzichmeebrengt.Voorborstkankeronderzoekendiespecifiek
naar lokale en regionale recidieven kijken, kunnen deze gegevens de onderzoekers
helpen bepalen hoeveel followͲup tijd nodig is voor betrouwbare resultaten. Als dat
korter zou kunnen, kan dat niet alleen kostenbesparing betekenmaar ookmogelijk
eerder beschikbaarheid van data voor de behandeling van patiënten. Voor andere




Uniforme definities verhogen de kwaliteit en betrouwbaarheid van onderzoeksͲ
resultaten,endaarmeeookdievanhetadviesdatweaanpatiëntengeven.Hetzelfde
geldtvoordeaandachtvoorhetbiologischgedragvandetumor.Datisinditproefschrift





































14.500 per annum in The Netherlands.2 It is hard to estimate the total amount of
funding invested in breast cancer research, but there are (fortunately) countless
governmental and nonͲgovernmental foundations, charities, and societies supporting
breastcancerresearchworldwide.Searching ‘breastcancer’yields,asofAugust2017,




This issue has becomemore stressing over the past decade and will becomemore
stressing in the future.Thesuccessofbreastcancer research in thepast fewdecades
has ledtofewrecurrencesandverygoodsurvivalformostbreastcancerpatients.This
meansthat inthecurrentera, largesamplesizesand long followuparenecessary for






prognostic information (i.e. by breast cancer subtype). This information can be
integrated inprognosticmodels thatareusedtoadvise individualpatientsabout their
treatment.AnexampleisAdjuvant!online.3Integratingthenewprognosticinformation
providespatientswithmoretailoredandthereforemoreaccurateinformation.
Furthermore, this thesis contains new information on prognosis of metastases in
contralateral lymph nodes and infraclavicular lymph nodes. This informationmay be
168
used to improve thenextversionof theTNMclassification4ofbreastcancer,which is
usedbyphysiciansandresearchersthroughouttheworld.
The knowledge generated in this thesis can also help make research easier, more
efficient, andmore transparent. The best way to achieve this, would be a uniform
formatfordatacollectiononanationwideorevenworldwidelevel.Afirststepcouldbe
amobileapplicationorwebsitewhichcouldbeusedbyresearchers,datamanagersand
physicians to classify a breast cancer recurrence (for instance according to the
standardizeddefinitionsfromChapter2).
Thenext step (forwhichmore knowledge, software, logistics, and commitment from
stakeholders worldwide would be required) should, in my opinion, go towards a
nationwide or worldwide, standardized database. This should safely store data with
regardtoprivacyandsensitiveinformation,beaffordableandcollectalltheinformation
that we need to move forward. Current cancer registries and clinical trial data
management strategies hold an enormous wealth of information, but still have
disadvantages,particularlythefactthattheyarenotstandardized(i.e.dataarecollected
inaslightlydifferentway)andcanbe inefficient,whichallmakesthemareverycostly.
Thereare currently severalwebbasedand tabletbasedapplications that safely store
research data using standardized forms, and some ofwhich can be linked to patient
records.Thisisahugestepforward.However,thesearemoredifficulttointegrateand




Implementation of new data in guidelines and classification systems works through
publication in peer reviewed journals and presentation of results on international
platforms. If the information is available and awareness is created, the datawill be
weighedtothetotalbodyofevidenceandimplementedasappropriate.
Implementation of uniform endpoint definitions particularly needs awareness among




definitions are implemented today in all new research protocols, itmay take several
yearsbeforewecancomparestudiesthatusedthesestandardizeddefinitions.
Implementation of standardized data registration internationally or nationally is an
extremely largeandextremelycostlyproject.Creatinganapplication thatwouldallow









challenges of trials requiring large sample sizes at high costs. Such efficiencywill be
beneficialtosociety:bothforbreastcancerpatientsandtheirfamilies,aswellasonan
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Itwas thebestof times, itwas theworstof times…Maarhet isvoltooid!Er zijneen
aantal mensen zonder wie ik niet gekomen was waar ik nu ben, zonder wie dit
proefschrifternooitgeweestwas,zonderwiehetpromoverenbeduidendminder leuk




zesdejaars student solliciteren omdat ik het idee van de BOOGͲstudie (destijds nog
SeNoMore)zo’n“goedonderzoeksdoel”vond.Zoblijdatikdegelegenheidhadomaan
tesluitenbijhetgroepjedatjeomjeheenhadverzameld.Hetdoorlopendthemavanje
wijze lessen isvoormijongetwijfeld“Jemoetstoppenalshetaf is”watnatuurlijkook
buitenonderzoekergbreedtoepasbaaris(mijnbadkamerkraanisjeeeuwigdankbaar).
Eenanderewijzelesisdekunstvanhetpresenterenengrantsschrijven,ofwelmensen
meenemen in je enthousiasme, transparant en eerlijk, maar wel zorgen dat
bescheidenheid of correctheid je niet onterecht tegenwerken (“Jij kunt gewoon geen
autozondermotorverkopen”,“Ikwilookhelemaalgeenautozondermotorverkopen”).
Daarnaasthoeomtegaanmethetfeitdatvrouwenonderlingsomsnogalbitchyzijnals
ze concurrentie ervaren, en dat caviaraces en sinaasappels volledig algemeen
geaccepteerd zijn in wetenschappelijke presentaties. Heb ik, ondanks mijn milde
eigenwijsheid,deboodschap tocheenbeetjebegrepen?Dankjewelvoor jegrenzeloze




Dr. Strobbe, beste Luc, vanaf het begin was je met je kritische blik een extreem
waardevol onderdeel van mijn promotieteam. Jaren ervaring als chirurg en als
onderzoeker zorgden meerdere malen voor het tegenwicht dat de stukken nodig
hadden om beter te worden. Prof. Stassen, hartelijk dank voor de steun en het
vertrouwen, natuurlijk met name in de laatste fase. Dank voor uw constructieve
bijdrage,ikkijkuitnaardevolgendesamenwerkingindekliniek!

Natuurlijk ook de Leden van de beoordelingscommissie: Prof. Beets, beste Geerard,
tijdensmijn semiͲarts periode in hetMUMC heb ik veel van u geleerd overwat een
goededokteriseninmijnhuidigebaanblijktdatdepatiënteninderegiounogsteeds




voor uw scherpe vragen en opmerkingen aan de microfoon bij congressen en
refereeravonden,wat u natuurlijk een ideale beoordelaar en opponentmaakt. Prof.
Heeren,BesteRon,sindsjekomstophetlabhebjememeerderemalenverrastmetje
rustenenthousiasme.Demixvanexpertise,onderzoekophoogniveau,waarderingvoor
je team, jeenthousiasmewaaruitmenalleenmaarkanconcluderendat jede leukste
baanvandewereldhebt,ikvindjeeenbewonderenswaardigonderzoekerenpersoon.
Prof.Ramaekers,besteFrans,ubedankikdubbel,nietalleenvoorhetvervullenvanhet
voorzitterschap van de beoordelingscommissiemaar ook omdat u als directeur van
GROW mij en vele medepromovendi zo veel kansen aanreikt om ons verder te




niet geweest. Speciaal voor Babette Frank, Marcel Bourgonje en Ellen van de Ven:
hartelijk dank, voor jullie inzet voor wat deze regio te bieden heeft op
onderzoeksgebied,maarookvoordeleukeactiviteiten.

Het BorstkankerͲteam in hetMUMC:Marc Lobbes, EstherHeuts, Kristien Keymeulen,
Prof. TjanͲHeijnen,Maaike de Boer, Prof. Liesbeth Boersma, uiteraard Elly, Jeanine,
Conny,MiekeenChristel,envanwisselendeduurookBartdeVries,KoenvandeVijver,




Veel van de gegevens die we voor de inhoud van dit proefschrift hebben kunnen
gebruikenzijnafkomstigvanIKNL.SabineSiesling,MarissavanMaaren,LindadeMunck,
Reini Bretveld, bedankt voor de prettige samenwerking, ik heb geleerd wat een
eindeloze schat aan informatie het jarenlange monnikenwerk oplevert, ik hoop dat
iedereenziethoewaardevoleengoedelandelijkeregistratieis.
DaarnaastSandervanKuijk,bedanktvoordejestatistischerelativeringsvermogenenje
creatieve oplossingen. Het is echt bewonderenswaardig hoe goed je de wereld van
getallenkanvermengenmetdewereldvanhetziekenhuis.









Women’swas inspiring, and the experiencewill definitely shapemy future career in
Surgeryandresearch.

Zonder Lori enRobertͲJanhad ik vastnooit geleerdom eenbeetje goede stukken te
schrijven(ofefficiëntomtegaanmetbepaaldecopromotoren).Lori,tijdenshetmaken
van jouw promotiefilmpje stuitte ik op een eindeloze hoeveelheid beeldmateriaal
waaruit bleek wat een toptijd het was: congressen, labuitjes, San Antonio Spurs,
cocktailsmetgummibeertjes,Stromaeconcertenennogveelmeer.RobertͲJan, ikwas




Lieve Briete, een beetje een impulsͲactie, maar de tussenstop in New York na het










zou willen hebben, zoals je precisie bij langdurige projecten en routineklussen, je







vande semiͲtuinnaarUNS40 verhuisden…Tochmiste ikTine,Nikkien Lotteweleen
beetje indiesemiͲcontext (nouja,DinerLesConsͲcontext insamenwerkingmetFrans),
gelukkigzijnjullienogsteedsinvoordiners!OpdiezelfdegangwasookJoosttevinden,







kunnen carpoolen, theedrinken, racefietsennaarwerk (hmmm)en jou kennende, so
muchmore.TweekamersverdernatuurlijkFrans(straksstajeinallestukjes!),tochaltijd
eenmysterie die activiteiten van jou in UNS50, er waren vaak lijstjes, schema’s en
geodriehoeken bij betrokken, of botten, en als het echt geheimzinnigwerd vetrok je
naarVenloomdaarom4.30AMallerleizakentescannen…Ikhoopweldat jeaanhet
eind van de rit kunt zeggen “No Kerbalswere harmed during the production of this
thesis”. En op dezelfde kamer David, coach van mijn allereerste racefietsrondje
waardoor ik dus eigenlijk nooit commentaar op de route zoumogen leveren, tevens
onverslagenmeesterinGeosenseenGeoGuessrenoja:SuitupFridaywaseendaverend
succes,maar Topless Tuesday is geen dingetje. En Kim, zo veel gezellige avonden in
Thembienmetfietsen,metalsdoorlopendthema“nevergofullretard”(metwisselend
succes), IreneFleur, ikbenecht fan van jouw rustendoelgerichtheidennatuurlijk je
interieursmaak,enmijnplantenkrijgentegenwoordigookgroenethee-.
Hoewel dinsdag gereserveerdwas voor Pubquizzen bij Edd’s, iswoensdag soms het
nieuwe vrijdag en dan zou Thembi niet hetzelfde zijn geweest zonder Audrey, Luuk,







dat ik jullie goede voorbeeld kan volgen!Maar natuurlijk ook aan alle andere lieve




huisjes, boompjes en beestjes, dan via een VikingͲhelm in Turkije tot kano’s en
wadlopen,ikbenblijdatdewereldnietmeeraltijdzwart/witis,enhoewelgrijswaarden
niet zo sexyklinktwordthet levenerveelbetervan!Sieltje, jeverdientmisschiende








echt onmisbaar de afgelopen 4 jaar! Daar voor natuurlijk ook, ‘Dierecteuren’ en
IJscohoofdpijn gaan je ook niet in de koude kleren zitten…maar promotieͲspecifieke
internetvondstenals ‘describeyourthesis inonesentence’ (omzomaareenvoorbeeld
tenoemen:lookedforagene,didn’tfindit)kunnennethetverschilmakenopeendag
die anders in het teken zou staan van rejection letters en onopgeslagen
worddocumenten.Nadeverdedigingmaareenseenroadtrip inFerrari2.0(alleengaat
iewatlangzamervan1naar100).
Sanne  (roomie!!!), hoewel je het soms goed weet te verbergen ben jij echt een
ontzettendbetrouwbare vriendinennatuurlijkhuisgenoot!Erwarenmisschien kleine
meningsverschillen,zoalshetvonnis inde zaakMartinevs.Alexander,de juisteplaats
om je vanGFTͲafval teontdoen,ende timing vanhet sluiten van je slaapkamerdeur,
maar uiteindelijk waren we het altijd eens over special breakfasts, BatmanͲposters,
festivals,misdaadseriesopNetflixenhetantwoordopdevraagWhatdoesthefoxsay?.




Inger en Julia, piglets, ik weet nu al dat jullie uitvoering van Het Mannenlied de
performanceofa lifetimegaatworden (nopressure).Alser tweemensenzijndiemij
goedkenneneneraltijdzijn,danzijnjulliehet.Danmaakthetdusooknietuitofhetin






opnemen als ikweereensdenkdat iets indebeschikbare tijd gewoononmogelijk is
maar het tochwelmoet. Dankjewel dat jullie altijdmet iets kleins de dagweten te

















Papaenmama,mijnmentoropdemiddelbare school zeial “jouwouders staanaltijd
achter jehe?”,waarop iknatuurlijkalleenmaar “ja” konantwoorden.Dank julliewel
voordeoneindige steun (opeenpaar scherpgeformuleerde sinterklaasgedichtenna).
Natuurlijkookvoordegezelligheid,hetthuiskomen,postͲwandeldinersinLimburg,die
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